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Abstract 
Hypertrophic scarring is a highly prevalent clinical condition and results from 
the dysregulation of the wound healing process. The exact mechanisms underpinning 
hypertrophic scar formation are still elusive. However, it has been demonstrated that 
reduced apoptosis, over-abundant collagen deposition, delayed re-epithelialization 
and exaggerated inflammation during wound healing lead to the formation of 
hypertrophic scars. Shikonin, an active component extracted from Radix Arnebiae, 
has been widely reported to induce apoptosis in different cancer cell lines. We 
therefore hypothesised that Shikonin will induce apoptosis in hypertrophic scar-
derived human skin fibroblasts (HSF) and may therefore hold potential as a novel 
hypertrophic scar treatment. Our preliminary data indicated that Shikonin inhibits 
cell proliferation and induces apoptosis in HSF in a dose-dependent manner via 
activating p-ERK, p-p38, Bcl-2 and caspase 3 signalling pathways. In this PhD study 
I further investigated the effects of Shikonin on both keratinocytes and HSF using the 
Transwell co-culture technique to gain a better understanding of the underlying 
mechanisms. I investigated the effects of Shikonin on the expression of cytokines, as 
well as evaluated the effects of Shikonin on TGF-β1-stimulated HSF. These studies 
indicated that Shikonin inhibits cell proliferation and induces apoptosis in Transwell 
co-cultured keratinocytes and HSF in a dose-dependent manner. Of interest, 
Shikonin at certain concentrations induces apoptosis in HSF but not in keratinocytes. 
I also demonstrated that Shikonin-induced apoptosis is triggered via the MAPK, 
intrinsic apoptosis and NF-κB signalling pathways. Additionally, my data indicated 
that Shikonin attenuates the expression of TGF-β1 in keratinocyte-HSF co-culture 
“conditioned” medium. Furthermore, we found that Shikonin inhibits collagen 
production and cell contraction by TGF-β1-stimulated HSF via the ERK/Smad 
signalling pathway. In conclusion, the data generated from this project provides 
compelling cellular and molecular evidence supporting the potential use of Shikoinn 
as a novel treatment for hypertrophic scars.  
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Chapter 1: Introduction 
1.1 BACKGROUND 
Hypertrophic scarring (HS) remains a challenging problem for clinicians. It is a 
highly prevalent condition and affects patients physically and mentally (Shamsi 
Meymandi et al., 2014). Clinically, HS are defined as “scars which contain excess 
collagen but still conform to the shape of the original wound” (Peacock et al., 1970). 
Although the frequency of HS varies between different ethnic groups and ages, it has 
been reported that the prevalence of HS can be up to 91.4% in burns and 44.6% after 
surgical incisions (Lewis & Sun, 1990). Patients report suffering from many side 
effects, including pain, itching, stiffness, loss of sensation and loss of joint mobility 
(Bock et al., 2006; van der Veer et al., 2009). In 2007, Aarabi et al. estimated the 
cost of HS treatment to be at least $4 billion annually just in the USA (Aarabi et al., 
2007).  
 
Although the exact mechanisms underpinning HS formation are still elusive, 
the formation of HS results from the dysregulation of the normal wound healing 
process (Sun et al., 2011). When sufficient collagen is formed during normal wound 
healing, the number of apoptotic fibroblasts sharply increases and myofibroblasts are 
removed via apoptosis (Moulin et al., 2004). In HS, however, these cells tend to 
persist and continue to produce large amounts of collagen (van der Veer et al., 2009). 
Indeed, it has been reported that HS have a four-fold decrease in cellular apoptosis 
compared with that found in normal wound scars (Aarabi et al., 2007). In addition, 
during normal wound healing, the high level of collagen synthesis present in the 
early stages decreases and returns to normal tissue levels as the wound closes 
(Mutsaers et al., 1997). Insufficient degradation and/or excessive production of 
collagen may therefore result in HS (Niessen et al., 1999). Keratinocytes (Kc) also 
play an important role in HS formation. In the early stages of wound healing, Kc 
reconstruct a functional epidermis (re-epithelialization) covering the exposed dermal 
surface (Koivisto et al., 2011). Delayed re-epithelialization often leads to HS 
formation (Machesney et al., 1998). 
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As of writing, there are no current therapies which can guarantee the 
improvement of HS. Many existing therapies are costly to the user. Moreover, each 
therapy has undesirable side-effects. For example, silicone dressings have been used 
in the treatment of HS since 1983 (Perkins et al., 1983), however, they must be worn 
for at least 12 hours daily, for a minimum of 2 months (Ahn et al., 1991; de Oliveira 
et al., 2001). This is inconvenient and uncomfortable, especially in warm climates. 
Other therapies, such as 5-Fluorourcacil (Haurani et al., 2009), onion extract 
(Wananukul et al., 2013), interferon (IFN) (Wang et al., 2007) and botulinum toxin 
(Xiao & Qu, 2012), have also been reported to be able to reduce HS, nevertheless, 
the use of these therapies needs to be further validated in clinical studies. Therefore, 
the development of a cost- and therapeutically-effective treatment with fewer side 
effects is of great importance for both patients and clinicians. 
 
1.2 HYPOTHESIS 
Currently the potential benefits of “natural” products for use in remediating HS 
are becoming increasingly important (Liu, 2015; Tark et al., 2015). The Chinese 
herbal medicine “Zi Cao” (Latin name: Radix Arnebiae), is a plant widely grown in 
China, Japan and Korea, and has been broadly used to treat wound healing and 
inflammation in Asian countries. Shikonin (SHI, C16H16O5), an active component 
extracted from Radix Arnebiae, has been demonstrated to possess a broad range of 
biological activities, such as anti-inflammatory (Liang et al., 2013), anti-bacterial 
(Shen et al., 2002), anti- angiogenic (Komi et al., 2009) and anti-tumorigenic 
properties (Hsu et al., 2004). Importantly, SHI has been extensively reported to 
induce apoptosis in many different cancer cell lines. Although SHI induces apoptosis 
in a variety of cancer cell lines, no studies have investigated the effects of SHI on HS 
related cells. Based on the importance of apoptosis in HS formation and the 
apoptosis-inducing ability of SHI, we hypothesised that SHI will induce apoptosis in 
hypertrophic scar-derived human skin fibroblasts (HSF) and therefore possess 
potential as a novel scar remediation therapy.  
 
To investigate this hypothesis the functional effect of SHI on HSF and the 
underlying mechanisms were investigated within our laboratory. Our results 
suggested that SHI inhibits the viability, proliferation and total amount of collagen 
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present in HSF in a dose-dependent manner (Xie et al., 2015). Our data indicated that 
SHI reduces the total amount of collagen in HSF by down-regulating collagen I 
(COL1A1), collagen III (COL3A1) and alpha-smooth muscle action (ACTA2) gene 
expression. The morphology of HSF treated with SHI showed cell shrinkage, 
chromatin condensation and membrane blebbing, indicating that SHI induces 
apoptosis rather than necrosis in HSF. This was confirmed using Terminal 
Deoxynucleotidyl Transferase dUTP Nick End Labelling (TUNEL) assay and 
Western blotting. Further studies indicated that SHI induces HSF apoptosis by up-
regulating the cleavage of caspase 3 and phospho-p38α/β (p-p38α/β), while 
concomitantly down-regulating Bcl-2 and phospho-extracellular signal-regulated 
kinase 1 and 2 (p-ERK1/2) expression in time- and dose-dependent responses.  
 
1.3 RESEARCH DESIGN 
The preliminary data described above suggested that SHI induces apoptosis in 
HSF and thereby may have potential as a novel HS therapy. This data was generated 
using a 2-D single cell type culture system using HSF, thus represents an 
environment that may not be relevant to the in vivo situation (Sun et al., 2006). In 
vivo, Kc are known to play important roles in the development of HS. This 
observation prompted us to recognise that we should also evaluate the effect of SHI 
on Kc. The overall aim of this PhD project is therefore to expand the preliminary 
studies reported from our laboratory and define the responses of HSF and Kc to SHI 
in ex vivo and in vitro skin models which are more similar to the human skin in vivo.  
 
Aim 1: Construct an In vitro HS model using De-epidermised Dermis Human 
Skin Reconstruction (DED-HSR)  
2-D cell culture systems maintain cells in a unnatural environment in which the 
tissue-specific architecture is lost (Pampaloni et al., 2007). 3-D cell culture, on the 
other hand, can maintain the physiological cell-cell and cell-ECM interactions, hence 
more accurately recapitulating the in vivo organisation than 2-D cell culture 
(Kleinman et al., 2003). For these reasons I proposed that a 3-D HSR model should 
to be employed to evaluate the effects of SHI on dermal fibroblasts and Kc. This will 
reduce the “gap” between studying the effects of SHI in monolayer cell culture and 
physiological tissues (Huang et al., 2004). The DED-HSR model developed in our 
 Chapter 1: Introduction 4 
laboratory has been demonstrated to be physiologically similar to the in vivo 
situation (Xie et al., 2010) and provides a superior in vitro cell culture model for the 
evaluation of various skin therapies (Lynam et al., 2010; Xie et al., 2010). In this 
PhD project, I aimed to construct an in vitro model of HS using the DED-HSR 
technique. This model will facilitate the analysis and characterisation of the 
therapeutic value of SHI.  
 
Aim 2: Examine the effects of SHI on primary Kc and HSF using Kc-HSF 
Transwell co-culture techniques  
As introduced above, Kc can also contribute to HS formation when wound 
healing (re-epithelialization) is delayed. While, the underlying mechanisms are still 
poorly understood, dysregulation in Kc-fibroblast crosstalk has been demonstrated to 
contribute to abnormal Kc function (Werner & Grose, 2003). The crosstalk between 
fibroblasts and Kc is primarily mediated by soluble cytokines and growth factors, 
rather than by direct interaction, since Kc and fibroblasts are located in different 
layers of the skin (Ghahary & Ghaffari, 2007). Evidence shows that the over-
secretion of growth factors, such as fibroblast growth factor (FGF) and transforming 
growth factor (TGF-β), from Kc promotes fibroblast proliferation and collagen 
synthesis (Zhang et al., 2009b). Kc have also been reported to decrease collagenase 
production in fibroblasts (Maas-Szabowski et al., 1999). The reduced expression of 
Interleukin-1 (IL-1) and increased expression of platelet-derived growth factor 
(PDGF) has also been demonstrated to contribute to HS formation (Niessen et al., 
2001). In my PhD project described herein, the effect of SHI on Kc and HSF was 
examined using the Transwell co-culture technique as this method has been widely 
used in a variety of skin studies (Lu et al., 2013; McLeod et al., 2014). This system 
allows Kc and fibroblasts to share the same culture medium without direct contact 
between cells; this is similar to the in vivo situation (Räsänen et al., 2008). 
Furthermore, the gene induction pathways in this model have been identified to be 
similar to the in vivo situation (Lim et al., 2002; Shephard et al., 2004). 
 
Aim 3: Evaluate the effect of SHI on TGF-β1-stimulated HSF 
TGF-β1 is widely reported to play an essential role in wound healing and HS 
formation (Yin et al., 2014). In particular, evidence indicates that TGF-β1 mediates 
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fibroblast proliferation, collagen production, extracellular matrix (ECM) deposition 
and myo-fibroblast differentiation during the wound healing process (Liu et al., 
2014a). Moreover, enhanced expression of TGF-β1 is reported to stimulate collagen 
synthesis in fibroblasts by activating the Smad2/3 signalling pathways, resulting in 
the accumulation of excess collagen (Wang et al., 2000b). The over-expression of 
TGF-β1 has also been demonstrated to contribute to the persistence of 
myofibroblasts. TGF-β1 stimulates normal dermal fibroblasts to differentiate into 
myofibroblasts by up-regulating αSMA expression (Varga & Abraham, 2007). Of 
note, the number of myofibroblasts, which are attenuated at the end of normal wound 
healing, persist at high levels in HS tissues (Hinz, 2007). Therefore, the effects of 
SHI on TGF-β1-stimulated HSF were investigated in Aim 3 of this PhD project. 
 
1.4 SUMMARY 
Excessive production of collagen and/or reduction of fibroblast apoptosis is 
believed to be the main cause of HS formation. Based upon centuries of anecdotal 
evidence that SHI reduces the formation of HS, I hypothesised that SHI will induce 
apoptosis of HSF (myofibroblasts) and therefore hold potential as a novel HS 
treatment. The overall goal of this project is to examine this hypothesis using 
sophisticated 2-D and 3-D in vitro cell culture approaches thereby gathering evidence 
in support of the development of SHI as a novel HS treatment. 
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2.1 SKIN 
In humans, the skin is the largest organ of the body. It is unsurprising therefore 
that skin provides many functions: it acts as a barrier for the body by preventing 
water loss, controls thermoregulation and excretion, and provides protection against 
ultraviolet radiation, toxic substances and pathogens (Brenner & Hearing, 2008; 
Elias, 2005; Hadgraft & Lane, 2009). There are two structural layers in the skin: the 
epidermis and the dermis (Ogawa & Hsu, 2013). A normal epidermis is a stratified 
epithelium made up of multiple layers of Kc, reflecting a continuous differentiation 
process from the basal layer to the outmost layer (Moriyama et al., 2014). Four 
distinct layers are present, the stratum basale, the stratum spinosum, the stratum 
granulosum and the stratum corneum, and these correlate with the different stages of 
Kc differentiation (Tsuruta et al., 2002). Kc also synthesise keratin, which is the key 
structural protein in human skin (Ramms et al., 2013). The basement membrane 
separates the epidermis and the dermis, acting as both a barrier and scaffold (Kelley 
et al., 2014). The dermis is a tissue consisting of many different cell types (Quinn, 
2004), including leukocytes (Zaba et al., 2007), dendritic cells (Ochiai et al., 2014) 
and fibroblasts (Ma et al., 2001). Collagen and elastin fibres are synthesised by the 
fibroblasts and make up 75% of the dry weight and 30% of the volume of the dermis 
(Venus et al., 2010).  
 
2.2 CUTANEOUS WOUND HEALING 
Cutaneous wound healing is the process by which skin repairs itself following 
surgery, trauma and burns (Ghahary & Ghaffari, 2007). The wound healing process 
is a cascade of events which can be divided into four phases: haemostasis, 
inflammation, proliferation and remodelling (Figure 2.1). Each phase requires the 
participation of different cell populations, including platelets, neutrophils, fibroblasts 
and Kc, as well as growth factors such as PDGF, insulin-like growth factor (IGF), 
epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), FGF, 
TGF-β and IL-1 (Enoch & Leaper, 2008; Williamson & Harding, 2004).  
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Figure 2.1. Stages of cutaneous wound healing. 
 
2.2.1 Haemostasis 
Following injury to skin tissue, a fibrin clot, mainly composed of blood cells 
and platelets (Arya et al., 2014), is immediately formed to establish haemostasis and 
coagulation (Golebiewska & Poole, 2014). The function of haemostais is to prevent 
the loss of blood. The platelets also secrete several growth factors, such as PDGF, 
IGF and EGF. These proteins not only initiate wound healing by stimulating nearby 
fibroblasts and macrophages, but also attract leucocytes and other cells from the 
immune system, and trigger the inflammation stage of wound healing (Enoch & 
Leaper, 2008). 
 
2.2.2 Inflammation 
The inflammation stage of wound healing is mediated by various cytokines and 
chemokines. Growth factors known to be involved in cutaneous wound healing 
include PDGF, tumor necrosis factor-α (TNF-α), TNF-β, TGF-β, EGF, and FGF. 
Additionally, cytokines such as IL-1, IL-6, IL-8, IL-10, and IFN-γ have also been 
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reported to play roles in the wound healing process (Morescalchi et al., 2013). It is 
well established that specific cytokines stimulate the infiltration of neutrophils and 
macrophages to the wound site. Neutrophils digest foreign debris by releasing 
proteolytic enzymes and remove bacteria through phagocytosis (Enoch & Leaper, 
2008; Martin & Leibovich, 2005). Meanwhile, blood monocytes change their 
phenotype and become macrophages, these release collagenase to debride the wound 
(Enoch & Leaper, 2008). Macrophages also produce cytokines, such as TGF-β1, to 
stimulate the migration of fibroblasts and epithelial cells (Mahdavian Delavary et al., 
2011).  
 
2.2.3 Proliferation 
The proliferation phase usually begins 3 days after wounding. This phase 
involves the activation of angiogenesis, fibroblast proliferation and migration, 
collagen synthesis and re-epithelialization (Kasuya & Tokura, 2014). During this 
stage fibroblasts migrate into the wound lesion and produce connective tissue and 
ECM (mainly collagen), assisting replacement of the blood clot with new granulation 
tissue (Fan et al., 2012a). Angiogenesis plays an essential role in the growth of 
granulation tissue and it is activated and controlled by VEGF, FGF and angiogenin 
etc (Liang et al., 2014). PDGF, TGF-β and IL-1 promote the synthesis of collagen 
from fibroblasts (Enoch & Leaper, 2008). A subset of fibroblasts alter their 
phenotype during this phase and exhibit the more proliferative myofibroblast 
phenotype (Darby & Hewitson, 2007). At the same time, Kc in the epidermis are 
stimulated to proliferate, migrate and reconstruct a functional epidermis (re-
epithelialisation), effectively, closing the wound lesion (Kioka et al., 2010). The re-
epithelialisation process is mediated by cytokines such as TGF-β, EGF and FGF 
(Enoch & Leaper, 2008). 
 
2.2.4 Remodelling 
In the final stage of wound healing, remodelling, the abundant disorganised 
collagen that has been protecting the wound site is degraded by collagenases (Sarkar 
et al., 2012). The degradation of collagen is mediated by collagenases produced by 
macrophages, Kc and fibroblasts (Mutsaers et al., 1997). Coincidentally, populations 
of cells will undergo apoptosis, however, this mechanism is poorly understood 
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(Akasaka et al., 2010). The granulation tissue finally evolves into a mature scar 
composed of fibroblasts and collagen. Scar tissue has a different texture and quality 
and reduced function compared to the original tissue (McDougall et al., 2006). 
 
2.3 HYPERTROPHIC SCAR FORMATION 
Scars are the normal end point of epithelial wound healing in mammals; only 
embryos are able to heal without scarring (Schwartzfarb & Kirsner, 2012). However, 
when wound healing is dysregulated, it may result in abnormal scars, such as keloid 
or HS (Figure 2.2) (Wolfram et al., 2009). The reasons underlying abnormal scar 
formation is poorly understood. HS is a highly prevalent condition, affecting patients 
physically and mentally (Shamsi Meymandi et al., 2014). It has been reported that 
reduced apoptosis at the end of wound healing, over-abundant production of 
collagen, delayed Kc function and pro-longed inflammation cause HS formation. 
Clinically, HS are defined as “scars which contain excess collagen but still conform 
to the shape of the original wound” (Peacock et al., 1970). The prevalence of HS 
varies in the population with association between gender, age and ethnicity, as well 
as wound depth and size, being reported in the literature. However, Lewis and Sun 
(1990) report that the frequency of HS can be up to 91.4% in burns, while 44.6% 
occur as a result of surgical incisions (Lewis & Sun, 1990). Patients with HS report 
that they suffer from many side effects, including pain, itching, stiffness, loss of 
sensation and loss of joint mobility (Bock et al., 2006; van der Veer et al., 2009).  
 
Some therapies are available for HS remediation (Chen & Davidson, 2005; 
Zurada et al., 2006), however, none have been reported which permanently eradicate 
or prevent HS formation (Alster & Handrick, 2000). Moreover, each therapy is 
associated with undesirable side-effects. For example, silicone dressings, used in the 
treatment of HS since 1983 (Perkins et al., 1983), requires the dressings to be worn 
for at least 12 hours daily, for a minimum of 2 months (Ahn et al., 1991; de Oliveira 
et al., 2001). Apart from the inconvenience this imposes, patients from warm 
climates suffer additional discomfort, pruritis and rashes (Nikkonen et al., 2001). Of 
note, the exact mechanism of the action of silicone on HS is still not fully 
understood. Despite the limited effectiveness of available therapies, the cost of HS 
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treatment is significant and has been estimated to be at least $4 billion annually in the 
USA (Arabi et al., 2007). 
 
 
 
Figure 2.2. Hypertrophic scars. (A) Hypertrophic scar on hand; (B) Hypertrophic scar on head. Images 
are obtained from Dr. Xiqiao Wang (Ruijin Hospital, Shanghai, China), personal communication. 
 
2.3.1 Scarless Wound Healing 
Mammalian embryos have been recognised to heal without the formation of 
scars for more than 20 years (Longaker et al., 1990). Concentrated research has 
identified that various cytokines and growth factors have been identified to 
contribute to the scarless healing of embryos. It has been reported that TGF-β1 
stimulates the differentiation of fibroblasts into myofibroblasts during adult wound 
healing (Midgley et al., 2013), however, myofibroblasts are absent in fetal wound 
healing (Kathju et al., 2012). An alternative form, TGF-β3 has been found to be up-
regulated in early gestation rat fetal skin compared with that in later gestation (Hsu et 
al., 2001). Upon application of exogenous TGF-β3, inflammation and ECM 
deposition in wound healing was observed to be reduced, thereby decreasing the 
formation of scars (Ohno et al., 2011). Peled et al. (2001) observed that while PDGF 
can be detected in both adult and fetal wounds, PDGF has a “short-lived” expression 
in fetal wounds (Peled et al., 2001). Further studies have confirmed that reducing the 
expression of PDGF contributes to the scarless wound healing phenotype (Wagner & 
Wehrmann, 2007).  
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Although the exact mechanisms underpinning HS formation remain elusive, 
the formation of HS is clearly associated with dysregulation of the wound healing 
process (Sun et al., 2011). Some of these dysregulated processes are described 
below.  
 
2.3.2 Apoptosis and Its Roles in HS Formation 
Apoptosis, also known as programmed cell death, occupies an essential role in 
various human diseases (Elmore, 2007), such as different types of cancer (Jazirehi, 
2010), Alzheimer's disease (Wang et al., 2012a), Parkinson's disease (Kim et al., 
2014), Huntington's disease (Ghavami et al., 2014), Amyotrophic lateral sclerosis 
(Pasinelli & Brown, 2006), chronic heart failure (Whelan et al., 2010) and some 
bacterial and viral infections (Danthi, 2011; Rice & Bayles, 2008). Two well-
established signalling pathways regulate apoptosis: the extrinsic (death receptor) and 
the intrinsic (mitochondrial) pathway. The extrinsic pathway triggers cell death via 
the transmembrane function of death receptors (Sessler et al., 2013). Once death 
receptors are activated, caspase 8 further transfers the death signal to caspase 3, 
which finally induces apoptosis (Fiandalo et al., 2013). The intrinsic pathway is 
activated by stilmuli directly targeting the mitochondria (Huang et al., 2014a). Those 
stimuli open the mitochondrial permeability transition pore, resulting in the release 
of cytochrome c (Garrido et al., 2006). Cytochrome c binds with apoptotic protease-
activating factor-1 (Apaf-1) and procaspase-9 to form an “apoptosome”, which 
induces apoptosis by further activating caspase 3 (Hill et al., 2004). The signalling 
pathways associated with apoptosis are summarized in Figure 2.3. 
 
Apoptosis has been reported to be essential for the reduction of cell numbers 
during the wound healing process (Greenhalgh, 1998). Reduced apoptosis results in 
an increased number of cells and increased formation of HS (Aarabi et al., 2007). 
When sufficient collagen is formed during late normal wound healing, the number of 
apoptotic fibroblasts sharply increases and myofibroblasts are removed via apoptosis 
(Desmouliere et al., 1995). In HS, however, myofibroblasts persist and continue to 
produce collagen (van der Veer et al., 2009). Indeed, it has been reported that HS 
have a four-fold decrease in cellular apoptosis compared with that found in normal 
wound scars (Aarabi et al., 2007). In addition, some apoptosis-related proteins have 
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been reported to be dysregulated in HS tissue. For example, Bcl-2, a protein that 
prevents cells from apoptosis, was found to be up-regulated in HS tissue compared 
with normal scar tissue (Wassermann et al., 1998).  
 
 
 
Figure 2.3. Extrisic and intrinsic apoptosis signalling pathways. “↑” indicates up-regulation; “↓” 
indicates down-regulation 
 
There is another commonly observed cell death pattern; necrosis. Necrosis-
induced cell death is triggered via karyolysis and cell swelling (Majno & Joris, 
1995), while apoptosis induces cell shrinkage, chromatin condensation and plasma 
membrane blebbing (Hacker, 2000). Unlike apoptosis, necrosis results in the loss of 
cell membrane integrity, while apoptosis involves no loss of membrane integrity 
(Elmore, 2007). Biochemically, necrosis is an energy-independent process (Eguchi et 
al., 1997), while apoptosis requires the participation of ATP (Butler et al., 2012). 
Further, DNA is digested randomly in necrosis whereas DNA digestion is tightly 
controlled in apoptosis (Mizuta et al., 2013). In addition, apoptosis may be induced 
by the release of cytochrome c into the cytoplasm while necrosis does not require 
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this (Saelens et al., 2004). Activation of apoptosis also requires the participation of 
caspase family proteins, such as caspase 3 (Nguyen et al., 2012). Of note, 
physiologically, necrosis simultaneously affects a group of cells while apoptosis is 
triggered in each individual cell (Levin, 1998). Necrosis can be triggered by non-
physiological factors, such as hypothermia (Zifman et al., 2010), hypoxia (Shan et 
al., 2013) or ischemica (Tudisco et al., 2014), while apoptosis can be induced by 
physiological stimuli (Tudisco et al., 2014). Furthermore, necrotic cells will be 
finally phagocytosed by macrophages, while apoptotic cells can be phagocytosed by 
either adjacent cells or macrophages (Erwig & Henson, 2008). Moreover, necrosis 
usually induces a host inflammatory response whereas inflammation responses are 
not observed during apoptosis process (Rock & Kono, 2008). Differences of 
apoptosis and necrosis are summarized in Table 1. 
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Table 1. Apoptosis VS Necrosis 
 
Necrosis Apoptosis 
Morphology 
Loss of membrane integrity (Elmore, 2007) No loss of integrity (Elmore, 2007) 
Swelling of cytoplasm and organelles (Hacker, 
2000; Majno & Joris, 1995)  
Cytoplasm shrinkage and nucleus condensation 
(Hacker, 2000; Majno & Joris, 1995) 
Biochemistry 
Energy (ATP) in-dependent (Butler et al., 
2012) 
Energy-dependent (Butler et al., 2012) 
Random digestion of DNA (Mizuta et al., 2013)  Internucleosomal DNA fragmentation (Mizuta et 
al., 2013) 
 Release of cytochrome c into cytoplasm (Saelens 
et al., 2004) 
 Participation of caspases (Nguyen et al., 2012) 
Physiology 
Affects groups of contiguous cells (Levin, 
1998)  
Affects individual cells (Levin, 1998) 
Triggered by non-physiological factors (Shan et 
al., 2013; Tudisco et al., 2014) 
Induced by physiological stimuli (Shan et al., 
2013; Tudisco et al., 2014) 
Phagocytosis by macrophages (Erwig & 
Henson, 2008) 
Phagocytosis by adjacent cells or macrophages 
(Erwig & Henson, 2008) 
Present of  inflammatory response (Rock & 
Kono, 2008) 
Absent of  inflammatory response (Rock & Kono, 
2008) 
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2.3.3  Over-abundant Fibroblasts Collagen Production and Roles of TGF-β1 
The key factor underlying HS formation is the imbalance of collagen turnover 
during the wound healing process. In normal wound healing the high level of 
collagen synthesis present in the early stages decreases and returns to normal tissue 
levels as the wound closes (Mutsaers et al., 1997). The degradation of collagen is 
mediated by proteases secreted by several cell types, including fibroblasts, epidermal 
cells and leucocytes (Mutsaers et al., 1997). Deficient degradation, or excessive 
synthesis of collagen, may therefore result in the development of HS (Linge et al., 
2005). The collagen production is regulated by growth factors, such as PDGF, TGF-
β, FGF and angiotensin (Werner & Grose, 2003). Dysregulation of those factors 
leads to an imbalance between collagen synthesis and degradation (Colwell et al., 
2005). 
 
Three isoforms of TGF-β have been described in humans: TGF-β1, 2 and 3 
(Schiller et al., 2004). Numerous studies have identified that TGF-β1 occupies a 
critical role in the formation of HS (Yin et al., 2014). Enhanced expression of TGF-
β1 is often observed in HS tissues (Tredget et al., 2006). Abnormally evaluated TGF-
β1 during wound healing has been demonstrated to lead to the over-accumulation of 
ECM, causing the formation of HS (Wang et al., 2008). TGF-β1 stimulates collagen 
production via the Smad signalling pathway (Derynck & Zhang, 2003), triggered by 
binding with its receptor TβRI. Binding of TGF-β1 to TβRI induces the 
phosphorylation of Smad2/3 (Derynck et al., 1998), resulting in translocation of 
phosphor-Smad into the nucleus, and modifying the expression of target genes such 
as collagen type I gene (Upadhyay et al., 2013). TGF-β1 is also demonstrated to 
support the differentiation of fibroblasts into myo-fibroblasts (Liu et al., 2014a).  
 
2.3.4 Delayed Kc Function 
Kc also play an important role in HS formation. In the final stages of wound 
healing, the Kc reconstruct a functional epidermis (re-epithelialisation) to protect 
exposed dermal tissue (Santoro & Gaudino, 2005). Abundant clinical evidence 
reveals that delayed re-epithelialisation often leads to HS formation (Brown et al., 
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2014). Other studies reveal that the degradation of collagen by fibroblasts is 
associated with factors secreted by Kc (Harrison et al., 2006). Delayed re-
epithelialisation may attenuate the delivery of these factors and thereby lead to 
deficient collagen degradation (Maas-Szabowski et al., 1999). Indeed it has been 
reported that when wound closure takes more than 21 days, the probability of the 
wound developing HS is more than 78% (Deitch et al., 1983).  
 
2.3.5 Other Causes 
Dysregulation in other aspects of wound healing may also contribute to the 
formation of HS. For example, the expression of fibronectin secreted by fibroblasts is 
one of the most important components of blood clotting and this decreases within a 
few days after re-epithelisation (Okiyama et al., 2011). In addition, some splice 
variants of fibronectin, such as the EDA fibronectin splice variant, have been 
demonstrated to play essential roles in regulating the differentiation of fibroblasts to 
myo-fibroblasts (Kohan et al, 2010). It has been proposed that prolonged fibronectin 
expression by fibroblasts may contribute to the formation of HS (Kischer et al., 
1989). Exaggerated inflammation may also lead to HS formation (Liu et al., 2013b). 
Furthermore, there is evidence that excessive angiogenesis contributes to the 
formation of HS (Zhang et al., 2014b). 
 
2.4 CROSSTALK BETWEEN KC AND FIBROBLASTS IN WOUND 
HEALING AND HYPERTROPHIC SCAR FORMATION 
Considerable evidence exists to support that the crosstalk between Kc and 
fibroblasts plays an essential role in both wound healing and HS formation. Kc and 
fibroblasts are located in the two different layers of the skin, separated by a basement 
membrane (Ghahary & Ghaffari, 2007). This crosstalk is mediated by soluble 
cytokines and growth factors, rather than by direct interaction. Indeed, it has been 
demonstrated in vitro that a large number of genes in fibroblasts code for growth 
factors and cytokines that are regulated by Kc-derived factors (Nowinski et al., 
2004). Many growth factors play vital roles in the wound healing process as they 
mediate the functions of wound healing-related cells. The functions of major growth 
factors known to be involved in wound healing are summarised in Table 2. 
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The cytokines involved in Kc-fibroblast crosstalk include IL-1, TGF-β, TNF-α 
and PDGF, and are produced predominantly by Kc, while KGF, IL-6, GM-CSF, 
KCF and IGF are produced mainly by fibroblasts. During the early phases of wound 
healing, Kc begin to proliferate under the influence of cytokines like IGF produced 
by the fibroblasts (Werner & Grose, 2003). Without signals from the fibroblasts, the 
Kc fail to re-establish a functional epidermis (El Ghalbzouri et al., 2004). Kc secrete 
IL-1, which stimulates the production of KGF and GM-CSF by fibroblasts and 
stimulates Kc proliferation and activation (Freedberg et al., 2001; Lukens et al., 
2012; Maas-Szabowski et al., 2001). IL-1 also induces fibroblasts to secret IL-6, 
which in turn improves Kc proliferation in wound healing (Grossman et al., 1989; 
Maas-Szabowski et al., 2000). In addition, the IGF that is produced by fibroblasts 
stimulates Kc proliferation and migration (Hyde et al., 2004; Lee et al., 2010). Kc 
also produce PDGF and TNF-α which enhance the synthesis of collagen by 
fibroblasts (Shephard et al., 2004). PDGF and TNF-α also stimulate fibroblasts to 
produce KGF, which in turn enhances Kc proliferation (Brauchle et al., 1994; Di et 
al., 2013). Moreover, TGF-β from Kc stimulates fibroblasts to become 
myofibroblasts (Mifkova et al., 2014). In contrast, TGF-β produced by fibroblasts 
induces Kc to return to an inactive state at the end stage of wound healing (Freedberg 
et al., 2001), leading to the down-regulation of collagen production and synthesis of 
cytokines by fibroblasts (Garner, 1998; Harrison et al., 2006). Evidence indicates 
that other cytokines from Kc, such as IL-7, IL-8, IL-10 and IFN, also contribute the 
wound healing, however, their roles in the Kc-fibroblast crosstalk remains unknown 
(Grone, 2002). Crosstalk between Kc and fibroblasts is summarised in Figure 2.4. 
 
As mentioned earlier, delayed re-epithelialisation is accompanied by a higher 
risk of HS formation. Ex vivo studies have revealed that Kc isolated from HS 
increase fibroblast proliferation and enhance collagen synthesis (Bellemare et al., 
2005; Harrison et al., 2006). The activated state of Kc usually ceases after the wound 
is re-epithelialised (Coulombe, 2003), however, Kc isolated from HS remain 
activated compared with normal scar-derived Kc (Andriessen et al., 1998; 
Machesney et al., 1998). Evidence indicates that the continued expression of Keratin 
6 and 16 in Kc can be a hallmark of delayed re-epithelialisation (Wawersik et al., 
2001; Wojcik et al., 2000). Other studies suggested that Kc in HS over-secrete 
growth factors, such as FGF and TGF-β, which promote fibroblast proliferation and 
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collagen synthesis, as well as decrease collagenase production in fibroblasts (Eto et 
al., 2012; Je et al., 2014). The reduced expression of IL-1 and increased expression 
of PDGF by Kc has also been demonstrated to contribute to HS formation (Salgado 
et al., 2012). 
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Table 2. Major cytokines in wound healing 
 
Growth Factor Functions References 
Platelet derived growth factor (PDGF) activates neutrophils and macrophages 
 
mitogen and chemoattractant for fibroblasts 
 
up-regulates pro-collagen synthesis 
(Ross et al., 1986) 
 
(Butt et al., 1995) 
 
(Abramov et al., 2012) 
Transforming growth factor beta 
(TGF-β) 
promotes synthesis of collagen in fibroblasts 
 
mitogen for fibroblasts 
 
chemotactic for fibroblasts 
 
regulator of fibroblasts differentiation 
(Wu et al., 2012) 
 
(Song et al., 2015) 
 
(Zou et al., 2014) 
 
(Zhang et al., 2015) 
Fibroblast growth factor (FGF) mitogen for Kc 
 
accelerates granulation tissue formation   
increases fibroblast proliferation 
(Werner, 2011) 
 
(Makino et al., 2010) 
Epidermal growth factor (EGF) enhances collagen synthesis (Choi et al., 2012) 
Insulin-like growth factor (IGF) activates fibroblasts  
stimulates collagen synthesis 
(Trosan et al., 2012) 
Vascular endothelial growth factor 
(VEGF) 
promotes angiogenesis in granulation tissue (Enoch & Leaper, 2008) 
Kc growth factor 
(KGF) 
stimulates Kc proliferation (Yamamoto-Fukuda et al., 2012) 
Granulocyte macrophage-colony 
stimulating factor 
 (GM-CSF) 
induces activation and differentiation of 
macrophages 
(Leal et al., 2011) 
Interleukin-1 (IL-1) enhances collagen synthesis (Thomay et al., 2009) 
Interleukin-6 (IL-6) stimulates Kc proliferation (Hernandez-Quintero et al., 2006) 
Tumor necrosis factor alpha (TNF-α) induces fibroblasts proliferation 
 
increases collagen synthesis 
(Feliciani et al., 1996) 
 
(Goldberg et al., 2007) 
Laminin-5 improves basement membrane formation (Min et al., 2010) 
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Figure 2.4. Crosstalk between Kc and fbroblsts.  “ ” indicates stimulation or up-regulation; “ ” 
indicates down-regulation or inactivation. 
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2.5 CURRENT HS TREATMENT 
A variety of therapies have been clinically used to treat HS. Although several 
novel therapies have also been reported to be effective in HS treatment, the use of 
these innovative therapies remains largely unvalidated. 
  
2.5.1 Silicone 
The use of silicone as a HS treatment was first reported in 1983 (Perkins et al., 
1983). Since this initial report a large number of studies have reported that silicone 
significantly reduces the hypertrophy of HS and is easy to apply (Ahn et al., 1991; 
Chittoria & Padi, 2013; Fette, 2006). Silicone is an effective treatment of HS; 
however, why HS respond to silicone is not understood. Research has shown that 
silicone maintains balanced occlusion and hydration in HS (Hoeksema et al., 2013). 
Previous studies conducted in our laboratory found that amphiphilic siloxane 
oligomers that elute from silicone dressings induce apoptosis in HSF (Lynam et al., 
2010). Regardless, silicone is a time-consuming treatment strategy (de Oliveira et al., 
2001) and is frequently accompanied by persistant pruritis and skin rashes (Nikkonen 
et al., 2001).  
 
2.5.2 Pressure Therapy 
Pressure therapy has been a clinical treatment for HS since 1960 (Brissett & 
Sherris, 2001). Pressure therapy is usually used in burns patients for prophylactic 
purposes (Macintyre & Baird, 2006). Pressure treatment is reported to reduce the 
ECM deposition by decreasing scar hydration (Brissett & Sherris, 2001). Evidence 
also suggests that pressure therapy increases collagenase activity by decreasing blood 
flow (Brissett & Sherris, 2001; Huang et al., 2013). However, pressure dressings are 
difficult to apply to scars located in anatomical flexures (Zurada et al., 2006). 
 
2.5.3 Laser Therapy 
Laser therapy is a popular and increasingly important strategy in managing HS. 
The mechanisms of how laser therapy contributes to the reduction of scars are 
unclear. One report claims that laser irradiation causes hypoxia in the HS tissue, 
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leading to apoptosis of fibroblasts (Kuo et al., 2005). Laser therapy has also been 
found to “normalize” dermal collagen and change the expression of TGF-β1 in HS 
(Makboul et al., 2014). However, high recurrence is observed in HS patients 
receiving laser therapy (Niessen et al., 1999). It has been shown that when laser 
therapy is used in combination with corticosteroid injections the recurrence rate is 
greatly reduced (Alster, 1997).  
 
2.5.4 Cryotherapy 
Cryotherapy, in which the HS tissue is rapidly frozen, has been found to induce 
damage to the microcirculation, and thereby result in shrinkage of HS tissues (Har-
Shai et al., 2003). Additionally, the collagen structure in HS has been found to be 
changed following cryotherapy (Sizov et al., 1990). However, hyper-pigmentation is 
an often reported side effect from patients receiving cryotherapy (Bloemen et al., 
2009).  
 
2.5.5 Corticosteroids Injection 
Coticosteroids are frequently used as a complementary therapy in combination 
with laser therapy. Coticosteroids directly inhibit fibroblast proliferation, thereby 
reducing collagen deposition (Manuskiatti & Fitzpatrick, 2002). Corticosteroids have 
been found to attenuate inflammatory responses in HS (Taheri et al., 2014). In 
addition, corticosteroids can activate collagenase, in turn improving collagen 
turnover (Hirshowitz et al., 1998). However, injection of corticosteroids is often 
accompanied by a burning sensation, skin atrophy and depigmentation (Brissett & 
Sherris, 2001). 
 
2.5.6 Other Therapies 
In addition to the commonly used therapies mentioned above, several other 
therapies are available for HS treatment. For example, 5-Fluorouracil, a commonly 
used anti-cancer drug, is reported to also be effective in HS treatment (Chen & 
Davidson, 2005). It has been demonstrated that 5-Fluorouracil reduces HS by 
inhibiting fibroblast proliferation (Fitzpatrick, 1999; Huang et al., 2010). However, 
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5-Fluorouracil causes several side effects, such as pain and hyperpigmentation 
(Fitzpatrick, 1999). Other therapies, such as bleomycin (Saray & Gulec, 2005), onion 
extract (Wananukul et al., 2013), botulinum toxin (Xiao & Qu, 2012), pentoxifylline 
(Isaac et al., 2010), tamoxifen (Gragnani et al., 2010), papain (Manosroi et al., 2012) 
and ginsenoside (Cheng et al., 2014) have each been reported to hold potential as a 
novel scar treatment. However, prospective studies have yet to validate these 
methods. 
 
2.6 ANIMAL HS MODELS 
To date the exact pathological mechanisms underpinning HS formation are still 
elusive. The lack of suitable animal models, in particular, is a major barrier towards 
gaining a better understanding the mechanisms of HS formation (Momtazi et al., 
2013). Various animal models for HS have been reported in the literature: several 
studies report that a rabbit ear HS model holds potential for HS study (Kloeters et al., 
2007; Yagmur et al., 2011), but prospective studies need to be undertaken to prove 
its feasibility and similarity to HS in human skin. While the use of rat HS models are 
relatively cost-effective (Cuttle et al., 2006), some of the mechanisms of wound 
healing in rats differ from the wound healing observed in humans (Ballas & 
Davidson, 2001). 
 
The current consensus is that pig skin has been demonstrated to be the best 
animal model in which to study HS. Pig skin has the closest similarity to human skin 
anatomically and physiologically (Cuttle et al., 2006). It has been demonstrated to 
have similar dermis-epidermis thickness ratio and size, as well as orientation and 
distribution of blood vessels in the dermis compared with human skin (Meyer et al., 
1978; Vardaxis et al., 1997). In addition, the similarity between HS in pig models 
and human HS has been further validated by comparing nerve density and growth 
factor expression (Liang et al., 2004; Zhu et al., 2004). Several different methods 
have been applied to induce HS in pig skin, including panniculus carnosus excision 
(Aksoy et al., 2002), coal tar application to the open wound (Zhu & Mo, 1996) and 
thermal injury (Cuttle et al., 2006). Interestingly, HS induction via chemical injury 
(such as coal tar) methods result in a lower rate of scar hypertrophy (Ramos et al., 
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2008).	   Therefore, thermal injury is more frequently utilised to guarantee HS 
formation compared with other types of wounding (Bloemen et al., 2009). The 
feasibility of this method has been comprehensively validated by our colleagues at 
the Royal Children’s Hospital (Cuttle et al., 2006). Although the pig scar model is 
expensive, we believe that the pig model created by our colleagues is the most 
suitable model for HS studies thus far.  
 
2.7 CHINESE HERBAL MEDICINE AND SHIKONIN 
At the time of writing, no current therapies guarantee the improvement of HS, 
with many of them being costly to the user. Recently, increased attention has been 
given to the potential benefits of “natural” products for use in remediating HS 
(Zhang et al., 2014b). Chinese herbal medicines (CHM) have been used for 
thousands of years in China and Eastern Asia. CHM often uses several components 
extracted from plants and relies on their combined actions. CHM has been reported 
to have favourable effects on many diseases and most CHM have been proven to be 
safe and effective with a clinical experience of thousands of years in China (Ye & 
He, 2010). However CHM is not widely accepted in Western society, primarily 
because the exact pharmacological mechanisms of CHM are not understood. 
 
“Zi Cao” (Radix Arnebiae), a Chinese herbal medicine, has been clinically 
used to treat burns and manage scars in China and Eastern Asia for centuries (Feng et 
al., 2008; Guo & Tang, 2006; Tang & Bhushan, 2010). However, the 
pharmacological mechanisms supporting its use are not well understood. SHI 
(Figure 2.5), also known as naphthoquinone pigment, is an active component 
extracted from “Zi Cao” and has been demonstrated to possess a broad range of 
biological activities, such as anti-inflammatory (Liang et al., 2013), anti-bacterial 
(Shen et al., 2002), anti-angiogenic (Komi et al., 2009) and anti-tumorigenic 
properties (Hsu et al., 2004). Reports indicate that the inhibitory activity on the 
synthesis of leukotriene B4 and 5- hydroxyeicosatetraenoic acid may contribute to the 
anti-inflammatory effect of SHI (Papageorgiou et al., 1999). SHI has been found to 
reduce the level of TNF-α, a pro-inflammatory mediator, at both transcriptional and 
post-transcriptional levels (Chiu & Yang, 2007). Wang et al. (1995) reported that 
SHI prevents vasculature from inflammation by suppressing mast cell degranulation 
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(Wang et al., 1995). Other studies have reported that SHI directly reacts with several 
types of reactive oxygen species (ROS) and exhibits antioxidative activity (Gao et 
al., 2000; Gong & Li, 2011). SHI has also been reported to have anti-bacterial and 
anti-viral activity, including anti-HIV-1 activity, which possibly may be due to its 
effects on topoisomerases (Li et al., 2012). 
 
 
 
Figure 2.5. Chemical structure of SHI. 
 
The anti-tumorigenic properties of SHI have been studied widely. Medicinal 
mixtures containing SHI are reported to be safe and effective in late-stage cancer 
treatment (Guo et al., 1991). Of relevance to this study, SHI has been extensively 
reported to induce apoptosis in many different cancer cell lines by differentially 
regulating various apoptosis-related proteins (Table 3). Studies showed that SHI may 
induce cell apoptosis by mediating reactive oxygen species (ROS) (Lee et al., 
2014a). Experimental analysis reveals that SHI combines with thiols, leading to the 
reduction of total thiols in cells (Duan et al., 2014). Reduction of thiols results in the 
up-regulation of ROS (Duan et al., 2014), damaging the oxidative membrane of 
mitochondria, attenuating mitochondria transmembrane potential and permeability-
barrier function (Huang et al., 2014b). Damaged mitochondria release cytochrome c 
into the cytoplasm, which in turn triggers apoptosis (Huang et al., 2014b). (Figure 
2.6) 
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Table 3. SHI-induced apoptosis in different cancer cell lines 
 
Full Name Abbreviation Expression Cells References 
Apoptosis-related 
cysteine peptidases 
Caspases (3, 8 
and 9) 
↑ A549 human non-small lung cancer 
cells Tca-8113 oral cancer cells 
B16F10 murine melanoma 
(Lim et al., 2007)        
(Min et al., 2008) 
(Rajasekar et al., 2012) 
Tumour 
Suppressor Protein 
p53 ↑ human colorectal carcinoma cells 
human glioma cells 
(Hsu et al., 2004) 
(Chen et al., 2012) 
B-cell lymphoma-
2 
Bcl-2 ↓ human colorectal carcinoma cells          
human malignant melanoma A375-S2 
cells Tca-8113 oral cancer cells                      
143B osteosarcoma cells 
(Fan et al., 2012c)       
  (Wu et al., 2004)         
(Min et al., 2008)     
(Chang et al., 2010) 
Bcl-2-associated 
death promoter 
Bad ↑ human colorectal carcinoma cells (Hsu et al., 2004) 
Bcl-2–associated 
X protein 
Bax ↑ human malignant melanoma A375-S2 
cells 
(Wu et al., 2004) 
Extracellular 
signal-regulated 
kinase 
ERK ↑ HL60 promyelocytic leukemia cells       
143B osteosarcoma cells 
Leukemia cells 
(Hashimoto et al., 1999)  
(Chang et al., 2010) 
(Han et al., 2012b) 
c-Jun N-terminal 
kinases 
JNK ↑ HL60 promyelocytic leukemia cells     
human epidermoid carcinoma cells     
chronic myelogenous leukemia (CML) 
cells 
(Hashimoto et al., 1999) 
(Singh et al., 2003) 
(Mao et al., 2008) 
Cyclin-Dependent 
Kinase Inhibitor 
p27 ↑ human colorectal carcinoma cells (Hsu et al., 2004) 
Mitogen-activated 
protein kinases 
p38 ↑ HL60 promyelocytic leukemia cells     
chronic myelogenous leukemia (CML) 
cells 
(Hashimoto et al., 1999) 
(Mao et al., 2008) 
Nerve Growth 
factor IB 
Nur77 ↑ NIH-H460 lung cancer cells (Liu et al., 2008) 
 
Table 3. Apoptosis-related changes in cancer cell lines exposed to SHI. ↑: up-regulation ↓: down-
regulation 
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Figure 2.6. SHI induces apoptosis via mediating ROS-mediated cascade. 
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2.8 PREVIOUS INVESTIGATIONS 
Based on the importance of apoptosis in HS formation and the apoptosis-
inducing ability of SHI, we hypothesised that SHI will induce apoptosis in 
hypertrophic scar-derived human skin fibroblasts (HSF) and therefore hold potential 
as a novel HS treatment. To address this hypothesis, we investigated the effect of 
SHI on HSF and gained early insights into the underlying mechanism. Our 
preliminary data (Xie et al., 2015) indicate that SHI inhibits HSF viability and 
collagen production in a dose-dependent manner. The effective does has been 
identified to be 0.5 and 1 µg/mL (Figure 2.7). 
 
 
 
Figure 2.7. Effects of SHI on HSF functional responses.  (A) HSF morphology following SHI 
treatment; (B) HSF viability and collagen metabolism were measured by Alamar Blue and Sirius Red 
stain, respectively. The data, expressed as the average percentage of control wells containing 10% 
FCS medium Error bars indicate mean ± SEM (n = 9). *p < 0.05 versus both 10% FCS and DMSO 
controls. Scale bar: 200 µm. 
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We also observed that HSF (16% ± 6.6%) go through apoptosis after exposure 
to SHI at 0.5 µg/mL compared to the control, while SHI at 1 µg/mL induces 82% ± 
8.5% HSF into apoptosis compared to the control. These data suggested that SHI 
induces apoptosis in HSF in a dose-dependent manner (Figure 2.8). 
 
 
 
 
Figure 2.8. Effects of Shikonin on induction of apoptosis in HSF. (A) Immuno-fluorescence of 
TUNEL positive HSF after treatment with SHI. Green indicates TUNEL positive cells (apoptotic 
cells) whereas blue localises the cell nucleus. Scale bar: 200 µm. (B) Calculation of SHI-induced 
apoptotic rate in HSF. 
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Our studies using western blotting also suggest that SHI-induced apoptosis in 
HSF may be triggered through the activation of p-ERK, p-p38, caspase 3 and 
reduction of Bcl-2 (Figure 2.9).   
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Figure 2.9. Effects of SHI on HSF protein expression.  SHI-induced protein changes were determined 
by Western blot. The experiment was repeated five times and the data depicted represents the results 
from analysis of cells from five patients. Proteins were collected from HSF treated with SHI for 1, 12 
and 24 h. The expression of proteins was detected using the Odyssey Infrared Imaging system. 
GAPDH was added as loading control.  
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2.9 SUMMARY 
HS result from the dysregulation of the wound healing process. The exact 
mechanisms of HS formation are not yet fully understood. It is known that “reduced 
apoptosis”, “over-abundant expression of collagen”, “delayed Kc function” and 
“prolonged inflammation” may each contribute to the formation of HS. As current 
therapies are not satisfactory, a novel HS treatment which is cost-effective and 
carries few side-effects is of great interest to both clinicians and patients. Although 
SHI has been widely reported to induce apoptosis in different cancer cell lines, the 
effect of SHI on HS related cells is yet to be investigated. Based on the importance of 
apoptosis in HS formation and the ability of SHI to induce apoptosis in cancer cell 
lines, we hypothesised that SHI will induce apoptosis in HSF and may therefore hold 
potential as a novel scar remediation therapy. The functional effect of SHI on HSF 
and the underlying mechanisms have been investigated in preliminary studies 
reported in Xie et al., (2015). The findings from our studies suggest that SHI inhibits 
the viability and proliferation of HSF and also reduces the total amount of collagen 
produced by HSF in a dose-dependent manner. This data also provides insights into 
mechanisms potentially underlying the actions of SHI on HS. The purpose of this 
PhD project was to further advance our understanding of the action of SHI on skin 
cells. 
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Chapter 3: Methodology 
3.1 PRIMARY CELL ISOLATION AND CULTIVATION 
3.1.1 Primary Kc Isolation and Cultivation 
Kc were isolated as previously described by Rheinwald and Green (Rheinwald 
& Green, 1975) from surgical skin discards obtained from St Andrew’s Hospital 
(Brisbane, Queensland, Australia) with patient consent and human ethics approval 
from both the hospital (#2003/46) and the Queensland University of Technology 
(#1300000063). Briefly, 0.125% Trypsin (#25200114, Life Technologies, Australia) 
was used to separate the epidermis from the dermis in the skin samples. The Kc were 
scraped from the upper surface of the dermis and transferred onto a lawn of 
irradiated mouse fibroblasts (i3T3; American Type Culture Collection, USA) in 
Green’s medium composed of a 3:1 mixture of Dulbecco’s Modified Eagle’s 
Medium (DMEM; #11995-065, Life Technologies) and Ham’s F12 medium 
(#21127-030, Life Technologies) and supplemented with 10% FCS (#SH3040101, 
Hyclone, USA), 1% v/v penicillin/streptomycin solution (#10378-016, Life 
Technologies ), 1% v/v 2 mM L-glutamine (#25030-081, Life Technologies), 10 
ng/mL human-recombinant EGF (#PHG0311, Life Technologies), 1 µg/mL insulin 
(#I2643, Sigma-Aldrich, Australia), 0.1 µg/mL cholera toxin (#C9903, Sigma-
Aldrich), 0.01% v/v non-essential amino acids solution (#11140-050, Life 
Technologies), 5 µg/mL transferrin (#T8158, Sigma-Aldrich), 0.4 µg/mL 
hydrocortisone (#H0888, Sigma-Aldrich) and 0.2 µM triiodothyronine (#IRMM469, 
Sigma-Aldrich). The cells were cultured in T-75 cm2 flasks at 37 °C, 5% CO2/95% 
air and the medium replaced every 2-3 days. 
 
3.1.2 HSF Cultivation 
HSF were purchased from Cell Research Corporation, Singapore. The cells 
were cultured in DMEM containing 10% FCS, 1% v/v penicillin/streptomycin 
solution and 1% v/v 2 mM L-glutamine in T-75 cm2 flasks at 37 °C, 5% CO2/95% 
air. The cell culture medium was replaced every 2-3 days. 
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In our previous studies, these HSF have been demonstrated to possess 91 up-
regulated and 8 down-regulated genes compared to normal fibroblasts (Xie, et al., 
2015). These dysregulated genes have been listed in Table 4. 
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Table 4. Dysregulated genes in HSF compared to normal fibroblasts 
 
                       up-regulated genes                down-regulated genes 
LOC728499, POM121 membrane glycoprotein (rat) 
pseudogene 
DLK1, delta-like 1 homolog 
(Drosophila) [Homo sapiens 
(human)] 
C7orf54, SND1 intronic transcript 1 (non-protein coding) SPC25, NDC80 kinetochore 
complex component [Homo 
sapiens (human)] 
RPL23AP13,  LOC644162 
ZBTB20, zinc finger and BTB domain containing 20 [Homo 
sapiens (human)] 
SF3B1, splicing factor 3b, 
subunit 1, 155kDa [Homo 
sapiens (human)] 
S100A1, S100 calcium binding protein A1 [Homo sapiens 
(human)] 
TAOK1, TAO kinase 1 [Homo 
sapiens (human)] 
MGC24103, uncharacterized MGC24103 [ Homo sapiens 
(human) ] 
CAST, calpastatin [Homo 
sapiens (human)] 
STARD13, StAR-related lipid transfer (START) domain 
containing 13 [Homo sapiens (human)] 
PPFIBP1, PTPRF interacting 
protein, binding protein 1 (liprin 
beta 1) [Homo sapiens (human)] 
LOC653158,  
 
BEX1, brain expressed, X-linked 
1 [Homo sapiens (human)] 
RCP9, calcitonin gene-related peptide-receptor component 
protein [Acyrthosiphon pisum (pea aphid)] 
 
LOC613037, nuclear pore complex interacting protein 
pseudogene [Homo sapiens (human)] 
 
C19orf40, chromosome 19 open reading frame 40 [Homo 
sapiens (human)] 
 
NLRP8, NLR family, pyrin domain containing 8 [Homo 
sapiens (human)] 
 
MEG3, maternally expressed 3 (non-protein coding) [Homo 
sapiens (human)] 
 
C8orf45, chromosome 2 open reading frame, human C8orf45 
[Gallus gallus (chicken)] 
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HSD17B7, hydroxysteroid (17-beta) dehydrogenase 7 [Homo 
sapiens (human)] 
 
KCNH6, potassium voltage-gated channel, subfamily H (eag-
related), member 6 [Homo sapiens (human)] 
 
C5orf28, chromosome 5 open reading frame 28 [Homo 
sapiens (human)] 
 
LOC90586, amine oxidase, copper containing 4, pseudogene  
TPM1, tropomyosin 1 (alpha) [Homo sapiens (human)]  
DENR, density-regulated protein [Homo sapiens (human)]  
LOC23117, nuclear pore complex interacting protein family, 
member B3 
 
OCIAD1, OCIA domain containing 1 [Homo sapiens 
(human)] 
 
SULT1A1, sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 1 [Homo sapiens (human)] 
 
USP49, ubiquitin specific peptidase 49 [Homo sapiens 
(human)] 
 
MCART1, solute carrier family 25, member 51 [Homo 
sapiens (human)] 
 
DUXAP3, double homeobox A pseudogene 3 [Homo sapiens 
(human)] 
 
TMEM17, transmembrane protein 17 [Homo sapiens 
(human)] 
 
TPM1, tropomyosin 1 (alpha) [Homo sapiens (human)]  
PLA2G2D, phospholipase A2, group IID [Homo sapiens 
(human)] 
 
FLJ44124, uncharacterized LOC641737 [ Homo sapiens 
(human) ] 
 
DLC1, DLC1 Rho GTPase activating protein [Homo sapiens 
(human)] 
 
 Chapter 3: Methodology 37 
HCG2P7,   
SLC25A20, solute carrier family 25 (carnitine/acylcarnitine 
translocase), member 20 [Homo sapiens (human)] 
 
MBD6, methyl-CpG binding domain protein 6 [Homo 
sapiens (human)] 
 
XRCC2, X-ray repair complementing defective repair in 
Chinese hamster cells 2 [Homo sapiens (human)] 
 
FKBP14, FK506 binding protein 14, 22 kDa [Homo sapiens 
(human)] 
 
LOC650128,   
ZNF483, zinc finger protein 483 [Homo sapiens (human)]  
DDB1, damage-specific DNA binding protein 1, 127kDa 
[Homo sapiens (human)] 
 
SFRP2, secreted frizzled-related protein 2 [Homo sapiens 
(human)] 
 
ZFHX3, zinc finger homeobox 3 [Homo sapiens (human)]  
ICA1, islet cell autoantigen 1, 69kDa [Homo sapiens 
(human)] 
 
PODN, podocan [Homo sapiens (human)]  
C21orf55, DnaJ (Hsp40) homolog, subfamily C, member 28 
[Homo sapiens (human)] 
 
GABPB2, GA binding protein transcription factor, beta 
subunit 2 [Homo sapiens (human)] 
 
PPA2, pyrophosphatase (inorganic) 2 [Homo sapiens 
(human)] 
 
LOC644931,  
FAM40B, striatin interacting protein 2 [Homo sapiens 
(human)] 
 
PIP5K2B, phosphatidylinositol-5-phosphate 4-kinase, type II, 
beta [Homo sapiens (human)] 
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DMC1, DNA meiotic recombinase 1 [Homo sapiens 
(human)] 
 
HNRNPU, heterogeneous nuclear ribonucleoprotein U 
(scaffold attachment factor A) [Homo sapiens (human)] 
 
C9orf80, INTS3 and NABP interacting protein [Homo 
sapiens (human)] 
 
ALPP, alkaline phosphatase, placental [Homo sapiens 
(human)] 
 
IL10, interleukin 10 [Homo sapiens (human)]  
MCM8, minichromosome maintenance complex component 8 
[Homo sapiens (human)] 
 
LOC613037, nuclear pore complex interacting protein 
pseudogene [Homo sapiens (human)] 
 
IL18, interleukin 18 [Homo sapiens (human)]  
PNPT1, polyribonucleotide nucleotidyltransferase 1 [Homo 
sapiens (human)] 
 
TNFSF14, tumor necrosis factor (ligand) superfamily, 
member 14 [Homo sapiens (human)] 
 
IFI27, interferon, alpha-inducible protein 27 [Homo sapiens 
(human)] 
 
BLZF1, basic leucine zipper nuclear factor 1 [Homo sapiens 
(human)] 
 
PRO1853, NADH dehydrogenase (ubiquinone) complex I, 
assembly factor 7 [Homo sapiens (human)] 
 
DUSP19, dual specificity phosphatase 19 [Homo sapiens 
(human)] 
 
RHBDL2, rhomboid, veinlet-like 2 (Drosophila) [Homo 
sapiens (human)] 
 
CHRNA5, cholinergic receptor, nicotinic, alpha 5 (neuronal) 
[Homo sapiens (human)] 
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PDE4C, phosphodiesterase 4C, cAMP-specific [Homo 
sapiens (human)] 
 
YRDC, yrdC N(6)-threonylcarbamoyltransferase domain 
containing [Homo sapiens (human)] 
 
HYPK, huntingtin interacting protein K [Homo sapiens 
(human)] 
 
PCDHB9, protocadherin beta 9 [Homo sapiens (human)]  
IL17RD, interleukin 17 receptor D [Homo sapiens (human)]  
STARD13, StAR-related lipid transfer (START) domain 
containing 13 [Homo sapiens (human)] 
 
LOC643396  
PTPLAD2, protein tyrosine phosphatase-like A domain 
containing 2 [Homo sapiens (human)] 
 
ZNF549, zinc finger protein 549 [Homo sapiens (human)]  
DDX51, DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 
[Homo sapiens (human)] 
 
FCAR, Fc fragment of IgA, receptor for [Homo sapiens 
(human)] 
 
LOC400464, uncharacterized LOC400464 [ Homo sapiens 
(human) ] 
ITGA7, integrin, alpha 7 [Homo sapiens (human)] 
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3.2 HUMAN SKIN RECONSTRUCTION (HSR) 
3.2.1 De-epidermised Dermis (DED) Preparation 
Skin samples were collected from St Andrew’s Hospital, Brisbane, QLD, 
Australia (Ethics #2003/46) and the Burns Department, The General Hospital of 
Ningxia Medical University, Yinchuan, Ningxia, China (Ethics #GHNMU81360294). 
Transferring buffers and DED washing buffer were made as shown in Table 5. 
Samples were washed sequentially in Transferring buffer 1 for 30 min, Transferring 
buffer 2 for 30 min and Transferring buffer 3 for 30 min. The subcutaneous tissues 
were removed from the skin samples and the samples were cut into 1.5 × 1.5 cm 
pieces. Each skin piece was placed into 1 M NaCl overnight at 37 °C. After 
removing the epidermis, the DEDs were washed in DED Washing buffering 1 for 48 
h, DED Washing buffer 2 for 48 h and DED Washing buffering 3 for 48 h. All DEDs 
were stored in FG medium at 4 °C before use (Maximum 14 days). 
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Table 5. DED buffer preparation 
 
 PBS DMEM Penicillin/Streptomycin Antibiotic/Antimycotic Gentamicin 
Transferring 
buffer 1 
500 mL   20 mL (4% v/v) 160 mg (0.32 µg/µL) 
Transferring 
buffer 2 
500 mL   10 mL (2% v/v) 80 mg (0.16 µg/µL) 
Transferring 
buffer 3 
500 mL  5 mL (1% v/v)   
DED Washing 
buffer 1 
 500 mL  20 mL (4% v/v) 160 mg (0.32 µg/µL) 
DED Washing 
buffer 2 
 500 mL  10 mL (2% v/v) 80 mg (0.16 µg/µL) 
DED Washing 
buffer 3 
 500 mL 5 mL (1% v/v)   
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3.2.2 HSR Preparation 
The DEDs were placed into a 24-well tissue culture plate with the dermis side 
uppermost. A steel ring with silicone washer was then placed on the top of each 
DED. HSF (2 × 104) were seeded onto the dermis side of each DED through the ring 
and allowed to attach in FG medium. After 3, 5, 7 or 10 days incubation, the DEDs 
were reversed (epidermis side on the top) and Kc (2 × 104) were seeded onto each 
DED through the ring and allowed to attach for another 2 days. The HSRs were then 
transferred onto the stainless steel grids with 6.5 mL FG medium. This permits the 
HSRs to be exposed at the air-liquid interface. After 7 days incubation, the HSRs 
were recovered and stained with 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT, 0.5 mg/mL) at 37 °C for 90 min to visualise 
the cells. Samples were finally placed in formalin for further processing. (Figure 3.1) 
 
 
 
Figure 3.1. Preparation of Human Skin Reconstruction (HSR).  
 
3.2.3 Hematoxylin and Eosin (H/E) Staining 
Formalin fixed HSR samples were trimmed as shown in Figure 3.2. Samples 
were cut following the blue dashed line as indicated in Figure 3.2. The region of 
interest (red arrow in Figure 3.2) was transferred into labelled processing cassettes 
and placed into 70% ethanol for processing, embedded in wax and sectioned. The 
sections were rehydrated, stained with H/E, dehydrated and mounted for 
 Chapter 3: Methodology 43 
photography. Images of each sample were captured using a Olympus BX41 camera 
mounted on a microscope (Olympus, Australia). 
 
 
 
Figure 3.2. Region of interest in HSR samples 
 
3.3 TRANSWELL CO-CULTURE 
Kc (4 × 104 cells/well) were placed onto the upper membrane face of the insert 
of the 12-well Transwell® plate (0.4 µm pore; #3460, Corning, USA) and allowed to 
attach for 24 h. HSF (6 × 104 cells/well) were placed into the lower chamber of the 
Transwell and allowed to attach for another 24 h. Different concentrations of SHI 
(0.5, 1 and 3 µg/mL) were dissolved in Dimethyl sulfoxide (DMSO; 0.0005%, 
0.001% and 0.003% v/v; Sigma-Aldrich) and added into the Transwell before 
commencing different assays (Figure 3.3). 
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Figure 3.3. Transwell co-culture approach. 
 
3.4 CELL FUNCTIONAL RESPONSES 
3.4.1 Reagent Preparation 
TGF-β1 (#616455, Merck, Australia) was dissolved in 4 mM hydrogen 
chloride (HCl) containing 0.1% bovine serum albumin (BSA; #A2153, Sigma-
Aldrich) and stored at -20 °C until use. SHI powder was purchased from the National 
Institute for the Control of Pharmaceutical and Biological Products, Beijing, China. 
SHI was dissolved in DMSO as a stock solution and stored at -20 °C until use. 
Phospho-ERK inhibitor U0126 (#9903) and Phospho-JNK inhibitor SP600125 
(#8177) were purchased from Cell Signalling, Australia. U0126 and SP600125 were 
diluted into DMSO at 10 µM and 50 µM before use. 
 
3.4.2 Cell Viability 
The effects of SHI on cell viability were investigated using the Alamar Blue 
assay. In this assay, Alamar Blue dye is reduced following contact with 
mitochondrial enzyme activity, resulting in a quantitative colour change from blue to 
pink (Al-Nasiry et al., 2007). Notably, the fluorescence of the pink product is able to 
be measured. Briefly, HSF (6 × 104 cells/well) were seeded into 12-well tissue 
culture plates and allowed to equilibrate for 24 h. Serial dilutions of SHI containing 5 
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ng/mL TGF-β1 were added to specific cultures in final concentrations of 0, 0.5 and 1 
µg/mL. Wells excluding TGF-β1 and SHI treatment was also included as controls. 
After 72 h incubation, Alamar Blue (300 µL, 0.1 µM, #R7017, Sigma-Aldrich) was 
added to each well and the plates were incubated at 37 °C for 1 h. Fluorescence in 
samples from the wells was detected at λex 570 nm and λem 590 nm using a Polar Star 
Optima Micro-plate Reader (Optima, Australia). 
 
3.4.3 Cell Proliferation 
The effect of SHI on cell proliferation was measured by CyQUANT® 
(#C35011, Life Technologies) assay (Jones et al., 2001). The CyQUANT reagent 
generates fluorescence following binding to nucleic acids. As cellular nucleic acid 
content is highly regulated, measurement of nucleic acid content using the 
CyQUANT reagent correlates with the number of cells present in the cultures. The 
proliferation can therefore be evaluated by measuring the fluorescence (Frankfurt, 
1980). Cultures were treated as described in Section 3.3 for the Transwell study or 
Section 3.4.2 for the TGF-β1 study. After 72 h of treatment, 300 µL of the 
CyQUANT reagent was added into each culture well. Following 30 min incubation 
at room temperature, fluorescence was measured in subsamples from the wells at λex 
485 and λem 520 using a Polar Star Optima Micro-plate Reader (Optima).   
 
3.4.4 Cell Apoptosis 
SHI-induced apoptosis was determined using the Terminal deoxynucleotidyl 
transferase dUTP Nick End Labeling assay (TUNEL; #11684795910, Roche, 
Australia). The TUNEL assay detects apoptosis by specifically labelling DNA 
fragments (Gavrieli et al., 1992). Kc and HSF were treated as described in Section 
3.3.  After 72 h incubation, the cells were first fixed in formalin, washed once in 
phosphate buffered saline (PBS; #10010023, Life Technologies) and finally 
permeabilised in 0.2% Triton X-100 (Sigma-Aldrich)/PBS. Cells treated with Dnase 
(#AMPD1, Sigma) or PBS were included as positive and negative controls. The 
samples were further washed in PBS and incubated with the TUNEL reaction 
mixture at 37 °C for 1 h. After incubation with the TUNEL reaction mixture, the 
samples were washed with PBS and mounted in SlowFade Gold antifade reagent 
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(#510634, Life Technologies) with added 4',6-diamidino-2-phenylindole (DAPI). 
The fluorescence images were captured with a Nikon Eclipse TE2000-U camera 
mounted on a fluorescence microscope (Nikon, Japan).   
 
3.4.5 Flow Cytometry 
Flow cytometry was also used to indentify SHI-induced apoptosis in Kc and 
HSF using the Dead Cell Apoptosis Kit with Alexa® Fluor 488 annexin V and PI 
assay kit (V13241, Life Technologies). Phosphatidyl serine (PS) is normally located 
on the cytoplasmic surface of the cell membrane, whereas it translocates from the 
inner to the outer leaflet of the membrane when apoptosis occurs (Schneider et al., 
2012).  Annexin V is the protein that binds with PS, therefore apoptosis can be 
identified using fluorophore-labeled Annexin V. Briefly, Kc and HSF were treated as 
described in Section 3.3. The cells were harvested after 12 h of treatment followed 
by washing with cold PBS twice. The cells were then resuspended in annexin-
binding buffer at 2 × 105 cells/mL and stained with Alexa® Fluor 488 annexin V and 
propidium iodide (PI) for 15 min at room temperature. The florescence was then 
measured at 530-575 nm emission and 488 nm excitation using FACSAria™ III Cell 
Sorter (Becton Dickinson, USA). 
   
3.4.6 Collagen Production 
The total amount of collagen present in the HSF cultures was assayed with 
Sirius Red staining. In brief, Sirius Red is a strong anionic dye that binds to collagen 
via its sulphonic acid groups reacting with basic groups in the collagen molecule 
(Chen et al., 2013). The HSF were initially treated as described in Section 3.4.2. 
After 72 h of treatment the cells were stained with Sirius Red (#365548, Sigma-
Aldrich) and incubated at 37 °C for 90 min. The plate was then washed with tap 
water and air dried overnight. The Sirius Red stain was dissolved in 0.1 M sodium 
hydroxide (NaOH) and the absorbance was read at 540 nm using a 96-well micro-
plate reader (Bio-Rad, Australia). 
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3.4.7 Cell Contraction 
Effects of SHI on TGF-β1-stimulated HSF contraction were determined using 
the Cell Contraction Assay kit (#CBA-201, Jomar Bioscience, Australia), as per the 
manufacturer’s protocol. Briefly, HSF were resuspended in medium containing 
different concentrations of SHI (0, 0.5 and 1 µg/mL) at 2 × 106 cells/mL. Then 0.1 
mL of cell suspension was mixed with 0.4 mL of collagen solution provided in the 
assay kit. This was then added into each well in a 24-well plate for 1 h at 37 °C. 
After collagen polymerization, 1 mL DMEM medium was added on the top the gels. 
The gels were incubated for 2 days, and then detached from the plate. TGF-β1 (5 
ng/mL) was added on the top of each gel and images of each gel were captured using 
a Nikon SMZ800 camera (Nikon) mounted on a microscope. The diameter of each 
gel was measured using a ruler at 0, 12, 24 and 48 h.  
 
3.5 MECHANISTIC STUDIES 
3.5.1 Western Blotting 
SHI-induced changes in cellular protein were determined by Western blot 
analysis. Cells were treated as described in Section 3.3 and 3.4.2. After 10 min, 30 
min, 60 min, 24 h and 48 h of treatment, the media were removed and total protein 
was collected in a lysis buffer containing 150 mM NaCl, 50 mM Tris, 1% sodium 
dodecyl sulphate (SDS), 1% Triton, protease inhibitor cocktail (PIC; 1 X as per the 
manufacturer’s instruction, Roche), 2 mM sodium vanadate and 10 mM sodium 
fluoride. The protein concentration was determined using the Bicinchoninic Acid 
(BCA; #23225, Pierce, USA) assay kit. Protein samples (10 µg) were first denatured 
(90 °C for 5 min) and then separated using Novex 4-12% Bis-Tris sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (#NPO0321BOX, Life 
Technologies). Finally the proteins were transferred onto nitrocellulose membranes. 
The membranes were incubated with primary antibodies overnight at 4 °C in 
Odyssey blocking buffer (#927-40000, LI-COR® Biosciences, USA). The primary 
antibodies are listed in Table 6. After washing in TBS/Tween 20 (50 mM pH 7.4 
Tris, 150 mM NaCl and 0.5% Tween 20), species appropriate secondary antibodies 
conjugated with AlexFlour 680 or 800 (Life Technologies) were applied. Images of 
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each immuno-blot were then captured using the Odyssey Infrared Imaging system 
and software (LI-COR® Biosciences). 
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Table 6. Primary antibodies used in Western blot 
 
Antibody Name Catalog No. Manufacturer 
ERK 9102 Cell Signalling, Australia 
Phospho-ERK (p-ERK) 9106 Cell Signalling, Australia 
JNK 9258 Cell Signalling, Australia 
Phospho-JNK (p-JNK) 9255 Cell Signalling, Australia 
p-38 sc-7972 Santa Cruz Biotechnology, USA 
Phospho-p38 (p-p38) sc-17852 Santa Cruz Biotechnology, USA 
Caspase 3 9662 Cell Signalling, Australia 
Bcl-2 2870 Cell Signalling, Australia 
Smad2/3 3102 Cell Signalling, Australia 
Phospho-Smad2/3 (p-Smad2/3) sc-11769-R Santa Cruz Biotechnology, USA 
αSMA ab5694 Abcam, Australia 
Bax 2772 Cell Signalling, Australia 
Cytochrome c 4272 Cell Signalling, Australia 
Collagen I sc-25974 Santa Cruz Biotechnology, USA 
IKK-α/β 9936 Cell Signalling, Australia 
p-IKK-α/β 9936 Cell Signalling, Australia 
NF-κB 9936 Cell Signalling, Australia 
p-NF-κB 9936 Cell Signalling, Australia 
I-κB 9936 Cell Signalling, Australia 
p-I-κB 9936 Cell Signalling, Australia 
GAPDH G8795 Sigma-Aldrich 
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3.5.2 Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-
PCR)  
qRT-PCR was used to evaluate the differential expression of genes in the cells 
following treatment with SHI. Genes of interest and primers (designed using Primer-
BLAST software on line www.ncbi.nlm.nih.gov/tools.primer-blast/) are listed in 
Table 7. Cells were treated as described in Section 3.3 and 3.4.2. Total RNA was 
extracted from the cell cultures at 10 min, 1 h, 24 h and 48 h after treatment using the 
Qiagen RNeasy Mini kit (#74134, Qiagen, Australia), following the manufacturer’s 
directions. RNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher 
Scientific, Australia) at 260 nm. Following RNA extraction, first strand cDNA 
synthesis was performed using SuperscriptTM III Reverse Transcriptase (#18080051, 
Life Technologies). qRT-PCR was then performed on an ABI 7500 Thermal Cycler 
(Applied Biosystems, Australia) using the SYBR Green (#4309155, Applied 
Biosystems) detection system, as per the manufacturer’s specifications. Expression 
of the target genes was first normalized to the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and then compared to the data from the control 
treatment group. 
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Table 7. Primers used RT-PCR 
 
Gene Name Corresponding Protein Name Primers: Forward (F) & Reverse (R) 
CASP3  Caspase 3 F: 5’-CGGAAGCAGTGCAGACGCGG-3’ 
R: 5’-GCTGCGAGCACTCACGAAACTCTTC-3’ 
BCL2  Bcl-2 F: 5’-TCAACCGGGAGATGTCGCCCC-3’ 
R: 5’-ACAAAGGCATCCCAGCCTCCGTT-3’ 
BAX  Bax F: 5’-AAACTGGTGCTCAAGGCCC-3’ 
R: 5’-TGAGGAGTCTCACCCAACCA-3’ 
CYCS   Cytochrome c F: 5’-ATGGTCTCTTTGGGCGGAAG-3’ 
R: 5’-CTCCCCAGATGATGCCTTTGT-3’ 
COL1A1  Collagen I F: 5’-ACGAAGACATCCCACCAATC-3’ 
R: 5’-AGATCACGTCATCGCACAAC-3’ 
COL3A1  Collagen III F: 5’-GCCTCCCGGAAGTCAAGGAGAAAG-3’ 
R: 5’-CTTTAGGACCGGGGAAGCCCATG-3’ 
ACTA2  αSMA F: 5’-CTGCTGAGCGTGAGATTGTC-3’ 
R: 5’-CTCAAGGGAGGATGAGGATG-3’ 
SMAD2  Smad 2 F: 5’-GGCGAATCGGCGGGG-3’ 
R: 5’-CCTCTTGTATCGAACCTCCCG-3’ 
GAPDH GAPDH F:5’-TCTTTTGCGTCGCCAGCCGAG-3’ 
R:5’-TGACCAGGCGCCCAATACGAC-3’ 
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3.5.3 Enzyme-linked Immunosorbent Assay (ELISA)  
The concentration of TGF-β1 and PDGF in “conditioned” media was 
determined from “Transwell” cultures using ELISA assay kits (#KAC1688, Life 
Technologies; #ab100624, Abcam). Briefly, media from each Transwell was 
collected after 24 and 48 h of SHI treatment. ELISA assays were then performed as 
per the manufacturer’s instructions and the absorbance was measured at 450 nm 
using a Polarstar Optima Microplate Reader (Optima). 
 
3.6 STATISTICAL ANALYSIS 
All experiments were repeated 3 times using cells from 3 different patients 
(biological replicates n = 3); for cells from each patient, the experiments were 
performed at least 3 times (technical replicates N = 3). The data are expressed as the 
percentage of the control (untreated) group. One-way ANOVA and Tukey’s post-hoc 
test were applied and p < 0.05 (ie. 95% confidence) was considered to be statistically 
significant. 
 
3.7 ETHICS  
Ethics approval for skin collection in The General Hospital of Ningxia Medical 
University was approved by the local hospital (GHNMU81360294). Human donor 
skin collection in Australia was approved by the St Andrew’s Hospital (2003/46) and 
the Queensland University of Technology (QUT: 1300000063). HSF were purchased 
from Cell Research Corporation, Singapore, and imported with Australian 
Quarantine and Inspection Service (AQIS, IP12018814) permission.  
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Chapter 4: Optimization Studies 
4.1 INTRODUCTION 
In our preliminary studies described at the end of Chapter 2, we reported that 
SHI inhibits cell proliferation and induces apoptosis in monolayer-cultured HSF. 
However, these data were generated using a 2-D single cell type culture system, an 
environment that may not be relevant to the in vivo situation (Sun et al., 2006). In 
order to further demonstrate the therapeutic value of SHI, I aimed to construct an in 
vitro HS model using the DED-HSR technique and then examine the effects of SHI 
on this 3D in vitro HS model.  
 
A number of HSR models have been developed by several investigators 
employing a variety of dermal substrates, such as artificial membranes (Mak et al., 
1991), DED (Chakrabarty et al., 1999), collagen gels (Gangatirkar et al., 2007) and 
biomaterial derived from hyaluronan with benzyl ester (Zacchi et al., 1998). Kc are 
usually cultivated on these dermal equivalents until a new epidermal layer is formed 
(Michel et al., 1997). While some models have been widely used in pre-clinical skin 
studies, disadvantages remain with these ex vivo models. For example, most of the 
components used to assemble the dermal substrates are non-defined and are extracted 
from animals or cultured cells. The use of “derived” components reduces the 
reliability and reproducibility of this model (Pampaloni et al., 2007). 
 
The DED-HSR model is the technique employed in our laboratory as a 
controlled 3D reconstructed model of human skin tissue. It involves seeding human 
Kc onto a native donor dermis and allowing an epidermis to form at the air-liquid 
interface (Topping et al., 2006). I elected to use the DED-HSR model because it is 
considered to be physiologically more similar to in vivo native human skin (Xie et 
al., 2010) and is regarded as a superior live in vitro model for the evaluation of 
various skin therapies (Lynam et al., 2010). For example, a fully differentiated 
epidermis, development of a stratum corneum and expression of keratin 6 (a wound 
repair marker) are well characterised features of this model. These parameters are 
considered to be key features of wound healing in vivo (Topping et al., 2006). The 
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major advantage of the DED-HSR model, however, is that it employs an acellular 
tissue matrix and retains the basement membrane (Topping et al., 2006). This is 
important as an intact basement membrane has been demonstrated to be essential for 
Kc attachment, growth and differentiation (Maas-Szabowski et al., 2001; Ralston et 
al., 1997; Segal et al., 2008).  
 
Other researchers in our laboratory have previously seeded normal fibroblasts 
and Kc into the DEDs, however, few fibroblasts were observed inside the DEDs. In 
this project, I aimed to increase the density of fibroblasts in the DED, since an 
increased number of fibroblasts is a feature of HS tissues. The HSR experiments 
were conducted as part of overseas fieldwork I undertook at the General Hospital of 
Ningxia Medical University, China, since HS skin samples are more abundant in 
China compared to what we could access in Australia. As reported in this chapter, I 
found it difficult to increase the fibroblast density in the HSR and was unable to 
obtain increased levels as found in HS tissues. In view of this I then examined the 
Transwell co-culture model as an alternative approach.  
 
Transwell co-culture is a technique that allows Kc to be co-cultured with 
fibroblasts by seeding Kc in a Transwell insert on top of the fibroblasts. Unlike 
feeder layer co-culture, the membrane pore (0.4 µm) underneath the insert of the 
Transwell permits Kc and fibroblasts to be co-cultured separately yet share the same 
medium. Importantly, cytokines secreted by either cell type are able to pass through 
the membrane, thus allowing cytokine communication between Kc and fibroblasts.  
 
In the preliminary studies outlined in Section 2.8 and reported in Xie et al., 
(2015), I had demonstrated that DMSO, which is used to dissolve the SHI power, has 
no effect on HSF viability and collagen production. I had also previously established 
that the effective dose of SHI is from 0.5 to 1 µg/mL. SHI at concentrations lower 
than 0.5 µg/mL have no effect on HSF viability and proliferation, whereas SHI at 
concentrations higher than 1 µg/mL strongly induce cell death in both Kc and HSF.  
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This current chapter reports my studies optimising the experimental conditions 
for the HSR model and the seeding approach employed, plus studies directed at 
determining treatment exposure time and the culture medium for use in the Transwell 
system.  
 
4.2 METHODS 
Primary Kc were isolated and cultivated in FG medium as described in Section 
3.1.1. HSF were cultivated in 10% FCS/DMEM medium as described in Section 
3.1.2. For HSR studies, the skin samples were collected from the General Hospital of 
Ningxia Medical University with ethics approval (GHNMU81360294). The DEDs 
were then prepared using these skin samples following the protocol explained in 
Section 3.2.1. HSF (2 × 104) were initially seeded into a steel ring on top of the 
dermis side of the DEDs with FG medium for 3, 5, 7 or 10 days. Kc (2 × 104) were 
then seeded onto the epidermal side of the DEDs for another 2 days. Each HSR was 
then transferred onto a grid in FG medium to enable culture at the air-liquid interface 
for 7 days (Details in Section 3.2.2). MTT was used to visualise the cells in the DED 
and H/E staining was used to analyse the structure of the HSR (Section 3.2.3). 
 
In the Transwell studies, Kc and HSF were individually seeded onto either the 
insert membrane (4 × 104 cells) or bottom of the Transwell chamber (6 × 104 cells) in 
FG medium. Cell proliferation was measured when the cells were seeded in both 
locations of the Transwell system (Figure 4.1) and cultured for different time (48, 72 
or 96 h) using the CyQUANT assay as described in Section 3.4.3. The seeding 
position and treatment time that resulted in the highest cell proliferation rate were 
selected as the experimental conditions for future studies. Once the seeding period 
and location of the cells were established, Kc and HSF were cultured in 3 different 
culture media formulations; this included serum free medium (SFM), EPI Life 
medium and FG medium. The medium that resulted in the highest cell proliferation 
rate for both cell types was selected as the culture medium for future studies. 
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Figure 4.1. Different seeding positions for the cells in the Tanswells.  Kc/X = Kc alone in the upper 
insert; X/HSF = HSF alone in the bottom well; Kc/HSF = Kc in the upper insert and HSF in the 
bottom well; X/Kc = Kc alone in the bottom well; HSF/X = HSF alone in the upper insert; HSF/Kc = 
HSF in the upper insert and Kc in the bottom well. 
 
4.3 RESULTS 
4.3.1 Morphology of Native Skin and HS Tissues 
Samples of native skin and HS tissue were obtained and analysed initially 
using H/E histology. This revealed, as expected, that HS tissues exhibit a higher 
density of fibroblasts compared to native skin (Figure 4.2). In addition, thick and 
rope-like fibers were observed in the HS tissue (Figure 4.2 B.d) but are not present 
in native skin. Furthermore, fibroblasts are noted to accumulate around blood vessels 
in HS tissues (Figure 4.2 B.b). In view of these characteristics, I attempted to 
construct an in vitro HS model which had characteristics that recapitulated native HS 
tissues. 
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Figure 4.2. H/E staining of native skin and HS tissue.  (A) Native skin; (B) HS tissue. “a, b, c & d” 
indicates randomly captured images at different magnification. Images were captured using Olympus 
BX41 microscope. Representative images were selected. Blue dots indicate cell nuclei. Scar bar = 100 
µm. Arrows indicate the areas where fibroblasts exist, fibroblasts accumulate or fibers are present. 
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4.3.2 DED Optimization 
To construct the HS-HSR model, DEDs from both native skin and HS tissues 
were evaluated. As can be seen from Figure 4.3, the density of collagen fibres (pink) 
in DED from native skin is lower compared to that observed in DED from HS 
tissues. In other words, DED from native skin has a less dense structure compared to 
DED from HS tissue.    
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Figure 4.3. H/E histology of DED derived from native skin and HS tissue.  (A) DED from native skin; 
(B) DED from HS. “a, b, c & d” indicates randomly captured images at different magnification. 
Images were captured using Olympus BX41 microscope. Representative images were selected. Scar 
bar = 100 µm. Arrows indicate areas of DEDs with fibroblasts. 
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After Kc and HSF were seeded onto the DEDs from both native skin and HS 
tissues, the HSR were then analysed using H/E staining as described in Section 3.2.3. 
As illustrated in Figure 4.4, fibroblast accumulation can be observed in DED from 
normal skin (Figure 4.4 A.a&c). However, fibroblasts are not detected in the DED 
derived from HS tissue. The epidermal layer formed on the top of the normal DED is 
notably thicker than that formed on HS DED. In light of the poor performance of the 
DED from HS tissue to act as a scaffold to support growth of the Kc and HSF, DED 
from native skin was selected for future studies directed at the construction of a HS 
model. 
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Figure 4.4. H/E staining of the HSR using DED from native skin and HS tissue. Kc and HSF were 
seeded onto the DEDs from both native skin and HS tissue. (A) Cells in normal DED; (B) Cells in 
scar DED. “a, b, c & d” indicates randomly captured images at different magnification. Images were 
captured using Olympus BX41 microscope. Representative images were selected. Blue dots indicate 
cell nuclei. Scar bar = 100 µm. Arrows indicate areas of fibroblast accumulation and formation of the 
epidermis. 
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4.3.3 HSR Optimization: HSF Cultivation Time 
Although I found that normal DEDs are more suitable for construction of the 
HS model than DED from HS tissues, cell density in the HSRs, particularly 
fibroblast density, is lower than observed in the original HS tissues (comparing 
Figure 4.4A to Figure 4.2B). 
 
I therefore increased the fibroblast seeding time to examine whether this would 
enable better fibroblast migration into the DEDs. Fibroblasts were cultured on the 
dermal side of the DED for 3, 5, 7 or 10 days. The DED was then flipped over and 
Kc were seeded on the top of the epidermal side of the DED for another 3 days. The 
HSRs were then cultured on the grids for 7 days at the air-liquid interface with 
medium changes every 3 days. As shown in Figure 4.5, few fibroblasts are detected 
inside the DED when the fibroblasts were cultured for 3 days (Figure 4.5 A). When 
fibroblasts were cultured on the DED for 5 days (Figure 4.5 B), no significant 
increase in fibroblast infiltration into the DED can be observed compared with that 
found at day 3. However, when fibroblasts were cultured for 7 days (Figure 4.5 C), 
fibroblast accumulation can be detected at the bottom of the DED. When the 
fibroblast cultivation time was increased to 10 days (Figure 4.5 D), fibroblast 
accumulation can be detected inside the DEDs. These data suggested that more 
fibroblasts migrate into the DED as the cultivation time past-seeding increases. 
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Figure 4.5. H/E staining of the HSR. HSF were seeded onto the dermis side of the DED for 3, 5, 7 or 
10 days. Kc were then cultured on the epidermal side of the DED for another 3 days. (A) HSF 
cultured for 3 days; (B) HSF cultured for 5 days; (C) HSF cultured for 7 days; (D) HSF cultured for 
10 days. “a, b, c & d” indicates randomly captured images at different magnification. Images were 
captured using Olympus BX41 microscope. Representative images were selected. Blue dots indicate 
cell nuclei. Scar bar = 100 µm. Arrows indicate fibroblasts in the DEDs. 
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4.3.4 Transwell Optimization: Seeding Position and Treating Time 
As described above, I observed that more fibroblasts migrate into the DED 
when the cultivation time post-seeding increased, however, the fibroblast density is 
still lower compared to what is observed in vivo in HS tissues (comparing Figure 
4.5D to Figure 4.2B). I therefore examined the Transwell co-culture technique as an 
alternative approach for the studies I wished to pursue in this project. In the in vivo 
situation, Kc are located at the outermost layer (epidermis) of the skin, while 
fibroblasts are beneath the epidermis (Venus et al., 2010). Therefore, Kc are usually 
placed on top of fibroblasts in Transwell co-culture to mimic the in vivo situation. 
However, to confirm the validity of this seeding regime, the Kc and HSF were 
seeded into the upper chamber or bottom of the Transwells separately and cell 
proliferation was then measured after varying periods (48, 72 or 96 h) of co-culture.  
 
As can be seen in Figure 4.6, co-cultured Kc or HSF exhibit higher cell 
proliferation rates compared to when they are cultured alone for 48 h when placed at 
the bottom of the Transwell. No statistical differences were observed between co-
cultured Kc or HSF and their corresponding mono-cell cultures when Kc or HSF 
were co-cultured in the insert. Whether cultured in either the upper insert or bottom 
well, Kc and HSF showed higher cell proliferation rates in co-culture compared to 
their corresponding mono-cell cultures at 72 h. Interestingly, after 96 h of co-culture, 
Kc and HSF proliferation was lower than in the corresponding mono-cell culture 
controls, regardless of the orientation of the seeding positions. Taken together this 
data suggests that the location of the Kc and HSF in the Transwell system does not 
affect the overall trends in cell growth. In addition, it suggests that Kc and HSF 
support enhanced proliferation of each other at 72 h, but after 96 h inhibitory effects 
occur. One possible reason for this is that co-cultured cells require more nutrients 
than mono-cultured cells; thus, essential nutrients may be consumed faster in co-
cultured cells than in mono-cultured cells. An alternative explanation may be that 
proliferation-inhibiting signals from Kc or HSF accumulate to critical levels after 96 
h of culture. That is, rather than supporting the proliferation of each other, the Kc and 
HSF may secrete factors that inhibit the proliferation of each other. For example, Kc 
are reported to reduce the proliferation and synthesis of collagen by HSF at the end 
of wound healing (Garner, 1998) (Harrison et al., 2006). The exact signalling 
 Chapter 4: Optimization Studies 66 
pathways involved in Kc-HSF crosstalk are yet to be elucidated. Nevertheless, given 
the structure of skin in vivo (i.e. fibroblasts are underneath Kc) and the decreased cell 
proliferation observed at 96 h, the approach of culturing Kc in the upper insert and 
HSF in bottom wells for 72 h was selected as for use in the experiments reported in 
this thesis.  
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Figure 4.6. Optimization of Kc and HSF seeding location and treatment time.  (A) Cell proliferation 
with Kc in the insert and HSF in the bottom well; (B) Cell proliferation with HSF in the insert and Kc 
in the bottom well. Kc/HSF = Kc and HSF co-culture (Kc in upper insert with HSF in the bottom 
well); HSF/Kc = HSF and Kc co-culture (HSF in upper insert with Kc in the bottom well); Kc/X = Kc 
alone in the insert; Kc-Kc/HSF = Kc in Kc/HSF co-culture; X/HSF = HSF alone in the bottom well; 
HSF-Kc/HSF = HSF in Kc/HSF co-culture;  X/Kc = Kc alone in the bottom well; Kc-HSF/Kc = Kc in 
HSF/Kc co-culture; HSF/X = HSF alone in upper insert; HSF-HSF/Kc = HSF in HSF/Kc co-culture. 
All experiments were repeated 3 times using cells from 3 different patients (biological replicates n = 
3); for cells from each patient, the experiments were performed at least 3 times (technical replicates N 
= 3). Statistical analysis was performed using One-way ANOVA with Tukey’s post-test. *p < 0.05. 
Error bar = SEM (n=3). 
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4.3.5 Transwell Optimization: Culture Medium 
While the co-culture approach and treatment duration are important, another 
important experimental condition to consider is the culture medium formulation. 
HSF in our laboratory are usually cultured in 10% FCS/DMEM medium, while Kc 
are normally maintained in FG medium, also containing 10% FCS (Rheinwald & 
Green, 1975). We have identified that fibroblasts are able to proliferate in both FG 
and 10% FCS/DMEM medium; however, the proliferation rate of Kc in 10% 
FCS/DMEM medium is much lower than that in FG medium. Other medium, such as 
serum free medium (SFM) (Pillai et al., 1988) and EPI Life medium (Slominski et 
al., 2005), are also widely used to culture Kc. To determine which culture medium to 
use in this project, Kc and HSF were cultured in each of these formulations and cell 
proliferation was measured using the CyQUANT assay. 
 
As can be seen from Figure 4.7, co-cultured Kc exhibited no significant 
differences in cell proliferation after 72 h compared to the mono-cultured Kc in all 3 
media. HSF in co-culture on the other hand, exhibited greater proliferation compared 
to mono-culture in all 3 media. Kc proliferation in the FG medium was slightly lower 
than observed in the SFM and EPI life formulations. However, HSF proliferation 
was substantially greater in FG medium compared to that measured in the SFM and 
EPI Life formulations. Considering these findings, I elected to use FG media for all 
future experiments reported hereon in this thesis.  
 
 
 
 
 
 
 
 Chapter 4: Optimization Studies 70 
 
 
Figure 4.7. Analysis of culture media formulation.  Kc and HSF were seeded in the insert and the 
bottom of the Transwell for 72 h. Cell proliferation was measured using the CyQUANT assay. FG = 
full green’s medium; SFM = serum free medium; EPI = EPI Life medium; Kc/HSF = Kc and HSF co-
culture (Kc in upper insert with HSF in the bottom well); Kc/X = Kc alone in upper insert; Kc-
Kc/HSF = Kc in Kc/HSF co-culture; X/HSF = HSF alone in the bottom well; HSF-Kc/HSF = HSF in 
Kc/HSF co-culture. All experiments were repeated 3 times using cells from 3 different patients 
(biological replicates n = 3); for cells from each patient, the experiments were performed at least 3 
times (technical replicates N = 3). Statistical analysis was performed using One-way ANOVA with 
Tukey’s post-test. *p < 0.05. Error bar = SEM (n=3). 
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4.4 DISCUSSION 
We have developed an in vitro 3-D HSR model in our laboratory for skin 
related studies (Topping et al., 2006). This model has been shown to recapitulate 
many features of human skin in vivo (Upton et al., 2008). Briefly, this model is 
constructed by seeding primary Kc on top of DED derived from native donor human 
skin. After 10-20 days cultivation at the air-liquid interface the Kc proliferate and 
differentiate to form a new epidermal layer which is physiologically similar to the in 
vivo epidermis. Given that fibroblasts play essential roles in HS formation, I aimed to 
modify our HSR model to create an in vitro model of HS tissue containing both Kc 
and HSF. As described in Section 4.3.3, while an increased number of HSF were 
found to migrate into the DED with time, the density of HSF cells in the DED 
remains lower than observed in vivo in HS tissues. These data suggest that the HSF 
density needs to be increased before this 3D model can be successfully used to 
evaluate the therapeutic value of SHI.  
 
One possible way to overcome this limitation is to stimulate the migration of 
HSF into the DED with the addition of growth factors, since specific growth factors 
are known to stimulate the migration of HSF. For example, IL-17 has been reported 
to stimulate fibroblast migration via the p38/NF-κB signalling pathways (Wu et al., 
2014b). IGF is also reported to improve human dermal fibroblast migration (Brandt 
et al., 2015). In addition, high mobility group box 1 (HMGB1) has been found to 
improve the migration of fibroblasts (Chitanuwat et al., 2013). Therefore, further 
optimization studies examining factors such as there may enable the fibroblast 
density in the HSR to be increased to levels suitable for the study of HS. 
 
Another approach to address the low density of HSF in the dermal substrate 
could be to employ 3-D collagen gels. The use of 3-D collagen gels to mimic the 
dermis is a popular approach in the generation of 3-D skin models. For example, 
Stamati et al. (2014) used this model to evaluate the effects of laminin on the 
formation of vascular networks (Stamati et al., 2014). Liu et al. (2014) also used this 
model to investigate the effect of myosin on fibroblast contraction (Liu et al., 
2014b). In addition, this model has been used to test the efficiency of different drugs 
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on hepatocarcinoma (Yip & Cho, 2013). One advantage of this approach is that it 
provides an ECM-cell communication environment, which is similar to the in vivo 
situation (Hall et al., 2013). 
 
Given the less than satisfactory results from trying to increase the density of 
HSF in the DED, I examined the use of the Transwell co-culture system; this co-
culture system has been widely used previously to study skin. My data indicate that 
there is no statistical difference between Kc or HSF grown in the upper insert or the 
lower bottom well of the Transwell (Figure 4.6). However, based on the fact that in 
skin Kc are located on the top of fibroblasts, I elected to culture the Kc in the upper 
insert and the HSF in the lower well of the Transwell apparatus over 72 h in FG 
media. This is consistent with approaches used by others. For example, Wang et al. 
(2012) adopted the Transwell strategy to investigate the effects of fibroblasts on Kc 
proliferation and migration (Wang et al., 2012b), while Shephard et al. (2004) used 
the Transwell apparatus to evaluate fibroblast differentiation (Shephard et al., 2004).  
 
While the duration of treatment is likely to be an important consideration, there 
is little agreement in the literature regarding what treatment times are optimal. 
Different studies have used various treatment times in Kc-Fibroblast Transwell co-
culture systems. Thus, Sun et al. (2014) measured fibroblast proliferation in response 
to Sestrin-1 at 24 h (Sun et al., 2014), while Glatzer et al. (2013) measured cell 
proliferation in response to Histamine at 48 h (Glatzer et al., 2013). These indicated 
that different proliferation assays and cell types yielded different answers. Based on 
my optimization study, I selected 72 h as the optimal period of treatment, since Kc 
and HSF exhibited optimal proliferation responses after this period, compared to 
what was observed at 48 and 96 h. 
 
FG medium is used extensively in our laboratory to cultivate skin cells 
(Fernandez et al., 2014). EPI Life medium is a commercially available medium 
designed especially for Kc cultivation (Zare et al., 2014), while other studies have 
used SFM for Kc cultivation (Chowdhury et al., 2012). I therefore investigated cell 
proliferation of Kc and HSF in each of these formulations. My results demonstrate 
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that HSF cultured in FG medium have a higher proliferation rate compared with HSF 
cultured in EPI Life or SFM medium. Although Kc in FG medium showed a lower 
proliferation rate compared to that in SFM and EPI life medium, I selected FG as the 
optimal medium for use in the remainder of this project.  
 
In conclusion, the data presented in this chapter indicated that HSF density in 
the DED remains lower than is found in vivo HS tissues, hence this HSR model 
needs further optimization. I instead optimized experimental conditions to support 
use of the Transwell co-culture system. My data indicate that seeding Kc in the insert 
and HSF at the bottom of Transwell and culturing for 72 h in FG medium is a 
feasible experimental approach since the Kc and HSF cells have the highest 
proliferation rate in these conditions compared what was observed in other 
experimental conditions. 
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Chapter 5: Effects of SHI on Transwell Co-
cultured Kc and HSF 
5.1 INTRODUCTION 
One theory accounting for the development of HS contends that reduced 
apoptosis at the end of wound healing leads to an increased number of fibroblasts 
(myofibroblasts) and therefore the formation of HS (Aarabi et al., 2007). The 
population of fibroblasts (myofibroblasts) is usually reduced via apoptosis in the late 
maturation phase of wound healing (Desmouliere et al., 1995). However, a large 
number of fibroblasts are reported to persist in HS (van der Veer et al., 2009). 
Consistent with this is the observation that HS have a four-fold decrease in cellular 
apoptosis compared with that present in normal wound scars (Aarabi et al., 2007). As 
noted earlier in this thesis, SHI, an active component extracted from Radix Arnebiae, 
has been demonstrated to induce apoptosis in different cancer cell lines (Duan et al., 
2014; Lee et al., 2014a). Based on the importance of apoptosis in HS formation and 
the apoptosis-inducing ability of SHI, we hypothesised that SHI may induce 
apoptosis in HSF. From a survey of the current literature, no study has reported the 
effects of SHI on skin related cells. We therefore undertook preliminary studies to 
examine the hypothesis that SHI may induce apoptosis in human HSF. 
 
These preliminary studies (Xie et al., 2015) demonstrated that SHI inhibits 
HSF proliferation and induces HSF apoptosis in a dose-dependent manner, and that 
SHI-induced apoptosis in HSF may be mediated via the ERK, p-38, caspase 3 and 
Bcl-2 signalling pathways. We further found that SHI down-regulates the total 
amount of collagen in HSF by reducing the expression of COL1A1, COL3A1 and 
ACTA2 genes. These data, focussed on HSF only, provided fundamental evidence 
supporting the potential application of SHI for the treatment of HS. To further 
evaluate the therapeutic value of SHI, additional investigations into the effect of SHI 
on both Kc and HSF were conducted, since each of these cell types is essential to 
wound healing and HS formation. In addition, the effects of SHI on the secretion of 
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cytokines in Kc-HSF co-cultures were also evaluated. The data reported in this 
chapter has been published by the Journal of Biomedical Science (Fan et al., 2015). 
 
5.2 METHODS 
Kc (4 × 104) and HSF (6 × 104) were seeded into the insert and bottom of the 
Tanswell as described in Section 3.3 using culture conditions reported in Chapter 4. 
SHI treatment (0.5, 1 and 3 µg/mL) and DMSO (0.0005%, 0.001% and 0.003% v/v) 
(vehicle controls) were then applied into the Transwell. Cell proliferation was 
measured using the CyQUANT assay at 72 h following the protocol in Section 3.4.3. 
SHI-induced apoptosis in Kc and HSF was identified using the TUNEL assay, as 
described in Section 3.4.4. SHI-induced apoptosis was further confirmed using flow 
cytometry as described in Section 3.4.5. Whole cell lysates were collected at 10 min, 
1 h, 24 h and 48 h following SHI and DMSO treatment. The total protein 
concentration in the lysates was measured using the BCA assay as per the 
manufacturer's instructions and then western blotting was used to detect the 
expression of the target proteins as described in Section 3.5.1. Total RNA was 
extracted at 1, 24 and 48 h following SHI and DMSO treatment. The first strand 
cDNA was synthesized using SuperscriptTM III Reverse Transcriptase, prior to RT-
PCR being performed on an ABI 7500 Thermal Cycler as described in Section 3.5.2. 
The effect of SHI on cytokine expression was measured using an ELISA as described 
in Section 3.5.3. One-way ANOVA and Tukey’s post-hoc test were applied and p < 
0.05 (ie. 95% confidence) was considered to be statistically significant. 
 
5.3 RESULTS 
5.3.1 SHI Inhibits Kc and HSF Proliferation in a Dose-dependent Manner 
Utilising the experimental conditions established earlier, I investigated the 
effects of SHI on donor Kc and HSF. Since SHI is not soluble in aqueous conditions, 
DMSO was used to dissolve the SHI powder. In view of this, different concentrations 
of DMSO were included in the experiments to act as vehicle controls. Kc and HSF 
were seeded into the Transwells as described in Section 3.1.3 and exposed to SHI 
(0.5, 1 and 3 µg/mL) and DMSO (0.0005%, 0.001% and 0.003% v/v) for 72 h. 
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Cultures containing Kc or HSF alone in the Transwells were also included for 
comparison. Cell morphology was recorded as a gross indicator of cell health. 
 
As shown in Figure 5.1, when cultured in either mono- or co-cultured 
conditions, DMSO at all concentrations and SHI at 0.5 µg/mL showed no effect on 
cell morphology compared to the untreated control. However, Kc and HSF were 
noted to be smaller in size when exposed to SHI at 3 µg/mL, in contrast to the 
untreated control. A dehydrated cell morphology was also observed in HSF exposed 
to SHI at 1 µg/mL for 72 h. Of interest, when Kc and HSF were co-cultured, they 
reached a higher cell density compared to cells in mono-culture. This suggests that 
the Kc and HSF provide a microenvironment that supports improved cell growth 
under these conditions. 
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Figure 5.1. Cell morphology of Kc and HSF.  (A) Kc in mono-culture; (B) HSF in mono-culture; (C) 
Kc in co-culture; (D) HSF in co-culture. Cells were treated with SHI and DMSO for 72 h. Images 
were captured using a Nikon ECLIPSE, TS100 microscope at 10X magnification. Representative 
images were selected from studies examining cells from 3 patients. Scale bar = 100 µm. 
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Having determined that DMSO had little deleterious effect on Kc and HSF, at 
least morphologically, the effect of DMSO on cell proliferation was examined. Data 
from the CyQUANT proliferation assay (Figure 5.2) indicated that DMSO had no 
effect on cell proliferation. However, at 0.5 µg/mL SHI was found to down-regulate 
mono-cultured HSF proliferation by 14.7% ± 2.2% compared to the untreated control 
(p < 0.05). SHI at 1 µg/mL attenuated mono-cultured Kc proliferation by 25.9% ± 
7.2%, mono-cultured HSF by 37.4% ± 1.9% and co-cultured HSF by 21.5 % ± 3.7% 
compared to the untreated control (p < 0.05). No effect of SHI at 1 µg/mL was 
observed on Kc proliferation when co-cultured. However, at 3 µg/mL SHI 
significantly reduced mono-cultured Kc proliferation by 73.8% ± 4.6%, co-cultured 
Kc by 39.5% ± 5.2%, single cultured HSF by 77.1% ± 0.9% and co-cultured HSF by 
50.7 % ± 7.6% compared to the untreated control (p < 0.05). 
 
These data suggested that SHI inhibits Kc and HSF proliferation in a dose-
dependent manner. Importantly, SHI at the same concentration had a greater impact 
on mono-cultured cell proliferation than co-cultured cell proliferation. In other 
words, co-cultured Kc and HSF appeared to confer some benefit that was resistant to 
SHI-induced reduction in cell proliferation. Interestingly, at 1 µg/mL SHI selectively 
attenuated co-cultured HSF proliferation, but not co-cultured Kc proliferation, 
illustrating that there is some cell type specificity at selected concentrations.  
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Figure 5.2. Effects of SHI on Kc and HSF proliferation. (A) Effects of SHI on Kc proliferation; (B) 
Effects of SHI on HSF proliferation. Cell proliferation was measured using the CyQUANT assay. The 
data was pooled as the percentage of the untreated control. All experiments were repeated 3 times 
using cells from 3 different patients (biological replicates n = 3); for cells from each patient, the 
experiments were performed at least 3 times (technical replicates N = 3). Statistical analysis was 
performed using One-way ANOVA with Tukey’s post-test. *p < 0.05 versus both the no-treatment 
and DMSO controls. Error bar = SEM (n=3). 
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5.3.2 SHI Induces Apoptosis in Kc and HSF in a Dose-dependent Manner 
Apoptosis, also known as programmed cell death, plays important roles in 
tumourigenesis, wound healing and development of the immune system (Elmore, 
2007). Morphologically, apoptotic cells can be identified by the appearance of cell 
shrinkage, chromatin condensation and plasma membrane blebbing (Hacker, 2000). 
To date two well-studied molecular signalling pathways of apoptosis have been 
revealed: the extrinsic (death receptor) and the intrinsic (mitochondrial) pathway. 
The extrinsic pathway triggers cell death via the transmembrane function of death 
receptors, such as the TNF receptor (Locksley et al., 2001). The death domain 
located on the death receptors plays key roles in transmitting the death signal (Rubio-
Moscardo et al., 2005). Once death receptors are activated, caspase 8 further 
transfers the death signal to caspase 3, which finally induces apoptosis (Fiandalo et 
al., 2013). The intrinsic pathway is induced by death receptor-independent stimuli 
that directly target the mitochondria (Huang et al., 2014a). The intrinsic pathway has 
a direct effect on the mitochondrial permeability transition pore, resulting in the 
release of cytochrome c into the cytoplasm (Saelens et al., 2004), where it binds with 
Apaf-1 and procaspase-9 to form an “apoptosome”. This structure induces apoptosis 
by further activating caspase 3 (Hill et al., 2004).  
 
The effect of SHI on apoptosis was assessed using the TUNEL assay as 
described in Section 3.4.4. The TUNEL assay detects endonuclease cleavage of 
DNA strand breaks (Kressel & Groscurth, 1994). As shown in Figure 5.3, no 
apoptotic cells were observed in either Kc or HSF after treatment with SHI at 0.5 
µg/mL and DMSO. Apoptotic cells were observed in HSF but not in Kc exposed to 
SHI at 1 µg/mL. However, at higher concentrations, SHI (3 µg/mL) induced 
apoptosis in both Kc and HSF. These data indicate that SHI induces apoptosis in a 
dose-dependent manner. However, at lower concentrations (i.e. 1 µg/mL), SHI 
selectively induces apoptosis in HSF but not in Kc. 
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Figure 5.3. SHI-induced apoptosis in Kc and HSF.  (A) SHI-induced apoptosis in Kc; (B) SHI-
induced apoptosis in HSF. Images were captured using a Nikon Eclipse TE2000-U microscope. Green 
(TUNEL) indicates DNA fragments from apoptotic cells, whereas blue (DAPI) localises the nuclei of 
all cells. All experiments were repeated 3 times using cells from 3 different patients (biological 
replicates n = 3); for cells from each patient, the experiments were performed at least 3 times 
(technical replicates N = 3). Scale bar = 100 µm. Representative images are depicted. 
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Data from flow cytometry (Figure 5.4) indicated that SHI at either 1 or 3 
µg/mL showed no effect on Kc apoptosis compared to the untreated group. However, 
SHI at 3 µg/mL significantly induces 56.16% ± 9.85% HSF population into apoptosis 
at 12 h compared to the untreated control (p < 0.05). This data suggests that SHI at 3 
µg/mL only induces apoptosis in HSF but not in Kc after 12 h of treatment. 
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Figure 5.4. Apoptosis in Kc and HSF determined by flow cytometry.  (A) Apoptosis rate in Kc and 
HSF following SHI treatment; (B) Quantitative analysis of SHI-induced apoptosis in Kc and HSF. Kc 
and HSF were treated with 0, 1 or 3 µg/mL SHI for 12 h and then stained with annexin V and 
propidium iodide as per the manufacturer's instructions. Flow cytometry was performed using 
FACSAria™ III Cell Sorter (Becton Dickinson). All experiments were repeated 3 times using cells 
from 3 different patients (biological replicates n = 3); for cells from each patient, the experiments 
were performed at least 3 times (technical replicates N = 3). Quantitative data from the 3 patients were 
pooled. Statistical analysis was performed using One-way ANOVA with Tukey’s post-test. *p < 0.05. 
Error bar = SEM (n=3). 
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5.3.3 Effects of SHI on MAPK and Intrinsic Apoptosis Signalling Pathways 
In order to investigate the mechanisms underlying SHI-induced down-
regulation of cell proliferation and stimulation of apoptosis, Western blot and RT-
PCR were used to identify differentially regulated proteins and genes in Kc and HSF 
exposed to SHI. 
 
Mitogen-activated protein kinases (MAPK), which includes extracellular 
signal-regulated kinase (ERK), c-Jun amino-terminal kinases (JNK) and p38, are a 
group of kinases that mediate key cellular bioactivities such as proliferation, 
differentiation, migration and apoptosis (McCubrey et al., 2006; Torii et al., 2006). 
ERK was the first member of the MAPK family to be identified. It is widely 
expressed in most tissues (Boulton et al., 1990). ERK1 and ERK2 are the two 
common isoforms of ERK and have been broadly reported to play vital roles in 
mediating cell proliferation. It has been demonstrated that ERK1/2 regulate cell 
proliferation via mediating cell cycle progress (Meloche & Pouyssegur, 2007). In 
quiescent cells, ERK1/2 are mostly located in the cytoplasm, however, ERK1/2 
accumulates in the nucleus once extracellular stimulation occurs (Lenormand et al., 
1993). ERK1/2 phosphorylates c-Fos protein and allows c-Fos to bind with c-Jun to 
form an activator protein 1 (AP-1) complex (Murphy et al., 2002; Whitmarsh & 
Davis, 1996). AP-1 induces the expression of cyclin D1, which stimulates the 
transition of G1 to S phase of the cell cycle by interacting with cyclin-dependent 
kinases (Shaulian & Karin, 2001). Of note, ERK has been demonstrated to contribute 
to the apoptosis process in different cell lines (Bavaria et al., 2014; Lee et al., 
2014b). 
 
The expression of p-ERK was observed to be up-regulated in Kc at 24 and 48 h 
and in HSF at 1, 24 and 48 h when exposed to SHI at 3 µg/mL (Figure 5.5). 
Additionally, SHI at 1 µg/mL increased p-ERK expression in HSF at 24 and 48 h. In 
contrast, SHI at 1 µg/mL had no detectable effect on p-ERK expression in Kc. These 
results indicated that SHI increases the expression of p-ERK1/2 in a dose-dependent 
manner. In addition, the phosphorylation of ERK1/2 induced by SHI occurs more 
rapidly in HSF than Kc.  
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Figure 5.5. Effects of SHI on ERK/p-ERK expression. (A) Effects of SHI on Kc ERK/p-ERK; (B) 
Effects of SHI on HSF ERK/p-ERK. Un = Untreated; S0.5 = SHI 0.5 µg/mL; D0.5 = DMSO 0.0005% 
v/v; S1 = SHI 1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 3 µg/mL; D3 = DMSO 0.003% v/v. 
Expression of protein was measured using the Odyssey Infrared Imaging system. All experiments 
were repeated 3 times using cells from 3 different patients (biological replicates n = 3); for cells from 
each patient, the experiments were performed at least 3 times (technical replicates N = 3). The data 
was pooled as the percentage of the untreated control. Representative images of the western blots are 
presented. At least 3 blots were performed. Bands from different treatment are derived from the same 
blot, while bands from different cells and time points are derived from the different blots. Statistical 
analysis was performed using One-way ANOVA with Tukey’s post-test. *p < 0.05 versus both the 
untreated and DMSO controls. Error bar = SEM (n=3). 
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JNK has 3 known isoforms: JNK1, JNK2 and JNK3 (Kyriakis et al., 1994). 
JNK1 and JNK2 are broadly expressed in various tissues, while the expression of 
JNK3 is mostly limited to neuronal tissues and cardiac myocytes (Bode & Dong, 
2007). The JNKs are strongly activated by cellular stress, such as heat shock, 
oxidative stress, DNA-damaging agents and UV irradiation (Bogoyevitch et al., 
2010).  In a similar fashion to ERK, JNKs are translocated from the cytoplasm to the 
nucleus after stimulation (Mizukami et al., 1997). JNK1 and JNK2 have been found 
to play essential roles in cell proliferation (Wazir et al., 2013), supporting the 
formation of the AP-1 complex and transcription of cell cycle-related proteins such 
as cyclin D1 (Sabapathy et al., 2004). A role for JNKs in regulating cell apoptosis is 
supported by the fact that fibroblasts isolated from JNK1/2 knockout mice are 
resistant to UV irradiation-induced apoptosis (Tournier et al., 2000). 
 
As shown in Figure 5.6, SHI at 3 µg/mL up-regulated the phosphorylation of 
JNK1/2 in Kc at 48 h and in HSF at 24 and 48 h, whereas SHI at 1 µg/mL only 
increased p-JNK1/2 expression in HSF at 48 h. These data indicate that SHI 
enhances the phosphorylation of JNK1/2 in a dose-dependent manner.  
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Figure 5.6. Effects of SHI on JNK/p-JNK expression.  (A) Effects of SHI on Kc JNK/p-JNK; (B) 
Effects of SHI on HSF JNK/p-JNK. Un = Untreated; S0.5 = SHI 0.5 µg/mL; D0.5 = DMSO 0.0005% 
v/v; S1 = SHI 1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 3 µg/mL; D3 = DMSO 0.003% v/v. 
Expression of protein was measured using the Odyssey Infrared Imaging system. All experiments 
were repeated 3 times using cells from 3 different patients (biological replicates n = 3); for cells from 
each patient, the experiments were performed at least 3 times (technical replicates N = 3). The data 
was pooled as the percentage of the untreated control. Representative images of the western blots are 
presented. At least 3 blots were performed. Bands from different treatment are derived from the same 
blot, while bands from different cells and time points are derived from the different blots. Statistical 
analysis was performed using One-way ANOVA with Tukey’s post-test. *p < 0.05 versus both the 
untreated and DMSO controls. Error bar = SEM (n=3).   
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There are 4 known isoforms of p-38: p-38α, p-38β, p-38γ and p-38δ (Cuadrado 
& Nebreda, 2010). p-38α and p-38β are widely expressed, however, p-38γ and p-38δ 
have a more limited expression profile (Jiang et al., 1997). In quiescent cells, p-38 
isoforms are present in both the cytoplasm and the nucleus (Ben-Levy et al., 1998). 
In response to stimulation, cytoplasmic p-38 will transfer to the nucleus (Raingeaud 
et al., 1995). p-38 isoforms mediate the expression of pro-inflammatory cytokines 
via the transcription factor nuclear factor-kappaB (NF-κB) (Karin, 2006). Deletion of 
p-38α results in the down-regulation of pro-inflammatory gene expression in 
epithelial cells (Kim et al., 2008). In addition, p-38 has been shown to regulate the 
cell cycle at the G1 to S and G2 to M transition points (Thornton & Rincon, 2009). 
Furthermore, p-38α has been found to participate in both the extrinsic and intrinsic 
apoptosis signalling pathways (Cuenda & Rousseau, 2007). 
 
As illustrated in Figure 5.7, Kc treated with SHI at 3 µg/mL attenuated p-p38 
expression in Kc after 48 h and in HSF after 24 and 48 h. At the lower dose of 1 
µg/mL SHI, the expression of p-p38 was only reduced in HSF and not in Kc after 48 
h. These results suggest that SHI affects p-p38 expression in Kc and HSF in a dose-
dependent manner. (Lee et al., 2014a) 
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Figure 5.7. Effects of SHI on p38/p-p38 expression. (A) Effects of SHI on Kc p38/p-p38; (B) Effects 
of SHI on HSF p38/p-p38. Un = Untreated; S0.5 = SHI 0.5 µg/mL; D0.5 = DMSO 0.0005% v/v; S1 = 
SHI 1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 3 µg/mL; D3 = DMSO 0.003% v/v. Expression of 
protein was measured using the Odyssey Infrared Imaging system. All experiments were repeated 3 
times using cells from 3 different patients (biological replicates n = 3); for cells from each patient, the 
experiments were performed at least 3 times (technical replicates N = 3). The data was pooled as the 
percentage of the untreated control. Representative images of the western blots are presented. At least 
3 blots were performed. Bands from different treatment are derived from the same blot, while bands 
from different cells and time points are derived from the different blots. Statistical analysis was 
performed using One-way ANOVA with Tukey’s post-test. *p < 0.05 versus both the untreated and 
DMSO controls. Error bar = SEM (n=3).  
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Caspases are a group of proteins that occupy pivotal roles in inflammation and 
apoptosis (McIlwain et al., 2013). Thus far, 17 members of the caspase super-family 
have been documented in the literature (Cohen, 1997; Eckhart et al., 2008; Hagar et 
al., 2013; Zhang et al., 2014a), with individual caspases contributing different roles 
during inflammation and apoptosis. Caspase 1 cleaves pro-IL-1 β to form the mature 
IL-1 β, an essential mediator in inflammation processes (Kostura et al., 1989). 
Caspase 8, an essential caspase in the extrinsic apoptosis signalling pathway, also 
regulates cell adhesion and migration via the activity of NF-κB (Stupack, 2013). 
Caspase 3, also known as the “executioner caspase”, is possibly the most important 
mediator in the apoptosis process (Kothakota et al., 1997). Caspase 3 catalyses the 
key final step in the apoptotic cascade (Reubold & Eschenburg, 2012).              
 
The cleavage of caspase 3 was observed in Kc after 48 h and in HSF after 24 
and 48 h when exposed to SHI at 3 µg/mL. At 1 µg/mL SHI was found to induce 
only the cleavage of caspase 3 in HSF after 48 h (Figure 5.8 A&B). At 3 µg/mL SHI 
attenuated CASP3 gene expression by 52.5% ± 14.9% and 35.6% ± 17.4% in Kc and 
HSF, respectively, after 48 h compared to the untreated control (p < 0.05) (Figure 
5.8 C&D). These data indicate that SHI induces the cleavage of caspase 3 in a dose-
dependent manner. It further indicates that Kc and HSF exhibit different sensitivities 
to SHI. 
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Figure 5.8. Effects of SHI on Caspase 3 protein and CASP3 gene expression.  (A) Effects of SHI on 
Kc caspase 3; (B) Effects of SHI on HSF capase 3; (C) Effects of SHI on Kc CASP3; (D) Effects of 
SHI on HSF CASP3. Un = Untreated; S0.5 = SHI 0.5 µg/mL; D0.5 = DMSO 0.0005% v/v; S1 = SHI 
1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 3 µg/mL; D3 = DMSO 0.003% v/v. Expression of 
protein was measured using the Odyssey Infrared Imaging system. All experiments were repeated 3 
times using cells from 3 different patients (biological replicates n = 3); for cells from each patient, the 
experiments were performed at least 3 times (technical replicates N = 3). The data was pooled as the 
percentage of the untreated control. Representative images of the western blots are presented. At least 
3 blots were performed. Bands from different treatment are derived from the same blot, while bands 
from different cells and time points are derived from the different blots. The expression of the target 
gene was normalized to GAPDH and then further converted to the percentage of the untreated control. 
Statistical analysis was performed using One-way ANOVA with Tukey’s post-test. *p < 0.05 versus 
both the untreated and DMSO controls. Error bar = SEM (n=3).    
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Members of the Bcl-2 family play key roles in regulating the intrinsic apoptosis 
signalling pathway and thereby mitochondria function (Chipuk et al., 2010). Some 
members of this family, including Bcl-2, Bcl-XL and Bcl-W, possess anti-apoptosis 
properties (Laulier & Lopez, 2012). Bcl-2 is located on the mitochondrial membrane 
and prevents the release of apoptotic factors from the mitochondria, such as 
cytochrome c (Kluck et al., 1997). Once cytochrome c is released to the cytoplasm, it 
directly activates caspases to induce apoptosis (Susin et al., 1996). 
 
As demonstrated in Figure 5.9, a decrease in Bcl-2 expression was observed in 
Kc at 48 h and in HSF at 24 and 48 h following treated with SHI at 3 µg/mL. SHI at 
1 µg/mL also reduced HSF Bcl-2 expression at 24 h. RT-PCR analysis (Figure 5.9) 
indicates that at 3 µg/mL SHI reduced BCL2 gene expression by 23.3% ± 1.8% in Kc 
and 51.9% ± 0.8% in HSF after 48 h relative to the untreated controls (p < 0.05). At 
1 µg/mL SHI attenuated BCL2 expression by 49.8% ± 0.8% in HSF compared to the 
untreated control (p < 0.05). 
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Figure 5.9. Effects of SHI on Bcl-2 protein and BCL2 gene expression.  (A) Effects of SHI on Kc Bcl-
2 protein expression; (B) Effects of SHI on HSF Bcl-2 protein expression; (C) Effects of SHI on Kc 
BCL2 gene expression; (D) Effects of SHI on HSF BCL2 gene expression. Un = Untreated; S0.5 = 
SHI 0.5 µg/mL; D0.5 = DMSO 0.0005% v/v; S1 = SHI 1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 
3 µg/mL; D3 = DMSO 0.003% v/v. Expression of protein was measured using the Odyssey Infrared 
Imaging system. All experiments were repeated 3 times using cells from 3 different patients 
(biological replicates n = 3); for cells from each patient, the experiments were performed at least 3 
times (technical replicates N = 3). The data was pooled as the percentage of the untreated control. 
Representative images of the western blots are presented. At least 3 blots were performed. Bands from 
different treatment are derived from the same blot, while bands from different cells and time points 
are derived from the different blots. The expression of the target gene was normalized to GAPDH and 
then further converted to the percentage of the untreated control. Statistical analysis was performed 
using One-way ANOVA with Tukey’s post-test. *p < 0.05 versus both the untreated and DMSO 
controls. Error bar = SEM (n=3).   
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In normal cells, Bax is primarily located in the cytoplasm, however, following 
stimulation by apoptosis-inducing agents, Bax changes its structure and thereby 
permeabilizes the mitochondrial membrane (Czabotar et al., 2014). Increased 
accumulation of Bax in the mitochondria leads to the release of apoptotic factors, 
such as cytochrome c, in turn triggering the apoptotic cascade (Renault & Manon, 
2011). 
 
As shown in Figure 5.10 A&B, no effect of SHI on the expression of Bax was 
observed in either Kc or HSF. However, at 3 µg/mL SHI was found to up-regulate 
the expression of BAX expression by 57.1% ± 17.1% in Kc and 31.4% ± 6.9% in 
HSF after 48 h compared to the untreated control (p < 0.05) (Figure 5.10 C&D). 
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Figure 5.10. Effects of SHI on Bax protein and BAX gene expression. (A) Effects of SHI on Kc Bax 
protein expression; (B) Effects of SHI on HSF Bax protein expression; (C) Effects of SHI on Kc BAX 
gene expression; (D) Effects of SHI on HSF BAX gene expression. Un = Untreated; S0.5 = SHI 0.5 
µg/mL; D0.5 = DMSO 0.0005% v/v; S1 = SHI 1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 3 
µg/mL; D3 = DMSO 0.003% v/v. Expression of protein was measured using the Odyssey Infrared 
Imaging system. All experiments were repeated 3 times using cells from 3 different patients 
(biological replicates n = 3); for cells from each patient, the experiments were performed at least 3 
times (technical replicates N = 3). The data was pooled as the percentage of the untreated control. 
Representative images of the western blots are presented. At least 3 blots were performed. Bands from 
different treatment are derived from the same blot, while bands from different cells and time points 
are derived from the different blots. The expression of the target gene was normalized to GAPDH and 
then further converted to the percentage of the untreated control. Statistical analysis was performed 
using One-way ANOVA with Tukey’s post-test. *p < 0.05 versus both the untreated and DMSO 
controls. Error bar = SEM (n=3).   
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Cytochrome c is a small (12 kDa) water soluble protein usually located in 
mitochondria (Zaidi et al., 2014). Cytochrome c is reported to play roles in a variety 
of biological processes, including acting as an antioxidant (Skulachev, 1998) and in 
regulating apoptosis (Tait & Green, 2013). Once released from mitochondria, 
Cytochrome c binds to Apaf-1 and then further combines with pro-caspase-9, 
resulting in the formation of the apoptosome (Li et al., 1997). The apoptosome 
activates caspase 3 which initiates the cell death pathway (Reubold & Eschenburg, 
2012).              
 
Data from Western blot analysis (Figure 5.11 A&B) revealed that the 
expression of Cytochrome c protein in Kc and HSF is unchanged after exposure to 
SHI. However, when treated with 3 µg/mL SHI, CYCS gene expression was 
increased by 66.2% ± 2.8% in Kc and 44.9% ± 12.9% in HSF after 48 h compared to 
the untreated control (p < 0.05) (Figure 5.11 C&D). 
 
 
(Belikova et al., 2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 5: Effects of SHI on Transwell Co-cultured Kc and HSF 111 
 
 
 
 
 
 
 
 
 Chapter 5: Effects of SHI on Transwell Co-cultured Kc and HSF 112 
 
 
 
 
 
 Chapter 5: Effects of SHI on Transwell Co-cultured Kc and HSF 113 
 
 
 
Figure 5.11. Effects of SHI on Cyrochrome c protein and CYCS gene expression.  (A) Effects of SHI 
on Kc Cyrochrome c; (B) Effects of SHI on HSF Cyrochrome c; (C) Effects of SHI on Kc CYCS; (D) 
Effects of SHI on HSF CYCS. Un = Untreated; S0.5 = SHI 0.5 µg/mL; D0.5 = DMSO 0.0005% v/v; 
S1 = SHI 1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 3 µg/mL; D3 = DMSO 0.003% v/v. 
Expression of protein was measured using the Odyssey Infrared Imaging system. All experiments 
were repeated 3 times using cells from 3 different patients (biological replicates n = 3); for cells from 
each patient, the experiments were performed at least 3 times (technical replicates N = 3). The data 
was pooled as the percentage of the untreated control. Representative images of the western blots are 
presented. At least 3 blots were performed. Bands from different treatment are derived from the same 
blot, while bands from different cells and time points are derived from the different blots. The 
expression of the target gene was normalized to GAPDH and then further converted to the percentage 
of the untreated control. Statistical analysis was performed using One-way ANOVA with Tukey’s 
post-test. *p < 0.05 versus both the untreated and DMSO controls. Error bar = SEM (n=3).   
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As introduced in the literature review in Chapter 2, excessive collagen 
production is a characteristic feature of HS (Niessen et al., 1999). I therefore 
examined the effects of SHI on the expression of collagen I at both the mRNA and 
protein levels. Collagen I is the most abundant protein in humans (Di Lullo et al., 
2002) and is mainly synthesized by fibroblasts (Rouillard & Holmes, 2014). During 
the proliferation stage of wound healing fibroblasts produces various ECM species, 
including collagen I (Clark, 1990). Dermal fibroblasts often change their phenotype 
to the more proliferative myofibroblasts (Darby et al., 2014). As the wound healing 
cascade matures, these cells normally die and collagen produced in the 
“proliferation” stage of wound healing will be degraded by collagenases. However, 
some individuals experience a failure of the collagen degradation resulting in HS 
formation (Tredget et al., 2014). 
 
Experimental analysis (Figure 5.12) indicates that SHI at 3 µg/mL reduces the 
expression of collagen I in HSF after 24 and 48 h compared to the untreated control. 
In addition, SHI at 1 µg/mL down-regulated the expression of collagen I in HSF after 
48 h compared to the untreated control. The expression of the COL1A1 gene was 
94.9% ± 2.3% and 80.5% ± 2.6% below the untreated control (p < 0.05) when 
exposed to SHI at 3 and 1 µg/mL for 48 h, respectively. Encouragingly, as little as 
0.5 µg/mL SHI reduced COLA1 gene expression by 15.9% ± 5.1% compared to 
untreated controls (p < 0.05). 
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Figure 5.12. Effects of SHI on collagen I protein and COL1A1 gene expression.  (A) Effects of SHI on 
HSF collagen I; (B) Effects of SHI on HSF COL1A1. Un = Untreated; S0.5 = SHI 0.5 µg/mL; D0.5 = 
DMSO 0.0005% v/v; S1 = SHI 1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 3 µg/mL; D3 = DMSO 
0.003% v/v. Expression of protein was measured using the Odyssey Infrared Imaging system. All 
experiments were repeated 3 times using cells from 3 different patients (biological replicates n = 3); 
for cells from each patient, the experiments were performed at least 3 times (technical replicates N = 
3). The data was pooled as the percentage of the untreated control. Representative images of the 
western blots are presented. At least 3 blots were performed. Bands from different treatment are 
derived from the same blot, while bands from different cells and time points are derived from the 
different blots. The expression of the target gene was normalized to GAPDH and then further 
converted to the percentage of the untreated control. Statistical analysis was performed using One-way 
ANOVA with Tukey’s post-test. *p < 0.05 versus both the untreated and DMSO controls. Error bar = 
SEM (n=3).   
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In addition to collagen I, collagen III, encoded by the COL3A1 gene, is 
produced in response to skin damage (Peeters et al., 2014). It is thought that collagen 
III contributes to the fibrillogenesis of collagen I (Liu et al., 1997). I examined the 
expression of  COL3A1 (Figure 5.13 A) and found it is reduced by 93.2% ± 1.9% 
when exposed to SHI at 3 µg/mL and 87.1% ± 0.3% when exposed to SHI at 1 
µg/mL compared to the untreated control for 48 h. 
 
As previously mentioned, a sub-set of fibroblasts change their phenotype to 
become  myofibroblasts in the proliferation stage of wound healing (Darby et al., 
2014). αSMA is considered as the marker of myofibroblasts as it is uniquely 
expressed in myofibroblasts (Novo et al., 2009). Over-expressed αSMA is 
commonly detected in HS tissues (Chen et al., 2014). My data (Figure 5.13 B) 
revealed that SHI at 3 µg/mL attenuated ACTA2 expression by 86.2% ± 1.7% 
compared to the untreated control (p < 0.05), whereas expression of ACTA2 was 
66.4% ± 2.4% below the untreated control (p < 0.05) when exposed to SHI at 1 
µg/mL for 48 h. Even at 0.5 µg/mL, SHI down-regulated ACTA2 expression by 
38.4% ± 18.0% compared to the untreated control (p < 0.05) in HSF after 48 h. 
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Figure 5.13. Effects of SHI on COL3A1 and αSMA gene expression. (A) Effects of SHI on HSF 
COL3A1; (B) Effects of SHI on HSF ACTA2. Un = Untreated; S0.5 = SHI 0.5 µg/mL; D0.5 = DMSO 
0.0005% v/v; S1 = SHI 1 µg/mL; D1 = DMSO 0.001% v/v; S3 = SHI 3 µg/mL; D3 = DMSO 0.003% 
v/v. All experiments were repeated 3 times using cells from 3 different patients (biological replicates n 
= 3); for cells from each patient, the experiments were performed at least 3 times (technical replicates 
N = 3). The expression of the target gene was normalized to GAPDH and then further converted to the 
percentage of the untreated control. Statistical analysis was performed using One-way ANOVA with 
Tukey’s post-test. *p < 0.05 versus both the untreated and DMSO controls. Error bar = SEM (n=3). 
 
 
HSF ACTA2 
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5.3.4 Link between MAPK and Intrinsic Apoptosis Signalling Pathway 
In the section described above (Section 5.3.3), I demonstrated that SHI up-
regulates p-ERK and p-JNK and down-regulates p-p38, caspase 3 and Bcl-2 
expression in Kc and HSF in a dose-dependent manner. Reports in the literature 
indicate that the MAPK proteins play roles in regulating cell apoptosis processes 
(Bavaria et al., 2014; Lee et al., 2014b). To investigate the roles of MAPK proteins 
in SHI-induced apoptosis, the p-ERK inhibitor U0126 and the p-JNK inhibitor 
SP600125 were used to block the phosphorylation of ERK and JNK in HSF when 
treated with SHI. 
 
The results of this analysis (Figure 5.14) indicated that U0126 significantly 
inhibits SHI-induced up-regulation of p-ERK in HSF at 24 h. When HSF were 
treated with both SHI (1 and 3 µg/mL) and U0126, there was no reduction of Bcl-2 
and cleaved caspase 3 observed, indicating that the blockage of p-ERK interrupts 
SHI-induced down-regulation of Bcl-2 and cleavage of caspase 3. However, 
reduction of Bcl-2 and cleavage of caspase 3 were detected when HSF were treated 
with both SHI and SP600125, indicating that blockage of p-JNK has no effect on 
SHI-induced apoptosis in HSF. 
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Figure 5.14. Link between MAPK and intrinsic apoptosis signalling pathway.  HSF were treated with 
SHI with or without U0126 (10 µM) or SP600125 (50 µM) for 24 h. S1 = SHI 1 µg/mL; S3 = SHI 3 
µg/mL. Expression of protein was measured using the Odyssey Infrared Imaging system. All 
experiments were repeated 3 times using cells from 3 different patients (biological replicates n = 3); 
for cells from each patient, the experiments were performed at least 3 times (technical replicates N = 
3). The data was pooled as the percentage of the untreated control. Representative images of the 
western blots are presented. At least 3 blots were performed. Bands from different treatment are 
derived from the same blot. Statistical analysis was performed using One-way ANOVA with Tukey’s 
post-test. *p < 0.05. Error bar = SEM (n=3).   
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5.3.5 Effects of SHI on NF-κB Signalling Pathway 
A large number of studies have reported that nuclear factor-kappaB (NF-κB) 
plays essential roles in regulating inflammation and apoptosis (Lappas, 2013; Yang 
et al., 2011). NF-κB normally binds with its inhibitor I-κB in an inactive state in the 
cytoplasm (Stancovski & Baltimore, 1997). Phosphorylation of I-κB kinase-α/β 
(IKK-α/β) leads to the phosphorylation and subsequently degradation of I-κB, thus 
inducing the phosphorylation of NF-κB (Gilmore, 2006). Activated (phosphorylated) 
NF-κB translocates into the nucleus and then regulates the transcription of its target 
genes, such as IL-1 and BCL2 (Hoffmann et al., 2006).   
 
As illustrated in Figure 5.15, expression of total IKK-α/β in HSF was 
attenuated when exposed to SHI at 3 µg/mL for 1 h compared to the control (p < 
0.05). However, the expression of p-IKK-α/β remained at the same level compared to 
the control. Down-regulation of p-I-κB and up-regulation of p-NF-κB were observed 
in HSF when exposure to SHI at 3 µg/mL for 24 and 48 h compared to the control. 
This data indicates that SHI at 3 µg/mL activates the NF-κB signalling pathway in 
HSF. 
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Figure 5.15. Effects of SHI on NF-κB signalling pathway.  HSF were treated with SHI (0, 1 and 3 
µg/mL) for 1, 24 or 48 h. S1 = SHI 1 µg/mL; S3 = SHI 3 µg/mL. Expression of protein was measured 
using the Odyssey Infrared Imaging system. All experiments were repeated 3 times using cells from 3 
different patients (biological replicates n = 3); for cells from each patient, the experiments were 
performed at least 3 times (technical replicates N = 3). The data was pooled as the percentage of the 
untreated control. Representative images of the western blots are presented. At least 3 blots were 
performed. Bands from different treatment and time points are derived from the same blot. Statistical 
analysis was performed using One-way ANOVA with Tukey’s post-test. *p < 0.05 versus the 
untreated controls. Error bar = SEM (n=3).  
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5.3.6 Effects of SHI on the Expression of Cytokines in Kc-HSF Co-culture 
Tissue homeostasis and function is carefully controlled. A variety of growth 
factors and cytokines regulate cellular responses such as proliferation, migration, 
differentiation, apoptosis and ECM synthesis (Moustakas et al., 2002). In particular, 
TGF-β1 is believed to drive the development of HS. The over-abundant expression 
of TGF-β1 is frequently observed in HS tissues (Du et al., 2013). Moreover, it has 
been shown that elevated TGF-β1 expression results in the over-accumulation of 
ECM, leading to the formation of HS (Zunwen et al., 2012). 
 
Another key cytokine involved in the wound healing process is PDGF 
(Kaltalioglu et al., 2013).  PDGF has been found to participate in inflammation 
(Pierce et al., 1992), proliferation (Li et al., 2008), angiogenesis (Man et al., 2005) 
and tissue remodelling (Jinnin et al., 2005); key wound healing processes. Evidence 
also indicates that PDGF secreted by endothelial cells results in the over-proliferation 
of fibroblasts (Bao et al., 2009). 
 
The expression of TGF-β1 and PDGF in Kc-HSF co-cultures using the ELISA 
assay as described in Section 3.3.3 was therefore examined. As shown in Figure 
5.16, when co-cultured Kc and HSF were exposed to SHI at 3 µg/mL, the expression 
of TGF-β1 was found to be down-regulated in the Kc-HSF co-culture medium by 
62.6% ± 2.3% after 24 h and 78.2% ± 6.2% after 48 h. However, no effect of SHI on 
the expression of PDGF was observed. 
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Figure 5.16. Effects of SHI on cytokine expression. (A) Expression of TGF-β1; (B) Expression of  
PDGF. Un = Untreated; S0.5 = SHI 0.5 µg/mL; D0.5 = DMSO 0.0005% v/v; S1 = SHI 1 µg/mL; D1 
= DMSO 0.001% v/v; S3 = SHI 3 µg/mL; D3 = DMSO 0.003% v/v. Cytokine concentration was 
measured according to the standard curve provided with the assay kit. All experiments were repeated 
3 times using cells from 3 different patients (biological replicates n = 3); for cells from each patient, 
the experiments were performed at least 3 times (technical replicates N = 3). The data was pooled as 
the percentage of the untreated control. Statistical analysis was performed using One-way ANOVA 
with Tukey’s post-test. *p < 0.05 versus the untreated controls. Error bar = SEM (n=3).  
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5.4 DISCUSSION 
Numerous reports have indicated that reduced apoptosis of fibroblasts at the 
end of wound healing results in an increased number of active fibroblasts, and 
thereby inducing the formation of HS (van der Veer et al., 2009). Indeed, it has been 
reported that HS have a four-fold decrease in cellular apoptosis compared with that 
found in normal wound scars (Aarabi et al., 2007). Consistent with our preliminary 
data, SHI has been found in the studies reported herein to inhibit HSF proliferation 
and induce HSF apoptosis in a dose-dependent manner, even in the presence of co-
cultured Kc. Moreover, ERK1/2, JNK1/2 and p38α/β have been widely demonstrated 
to play vital roles in the regulation of cell proliferation and apoptosis (Cagnol & 
Chambard, 2010b; Dhanasekaran & Reddy, 2008; Zhang & Liu, 2002). The data 
shown here suggest that SHI induced reduction of proliferation and induced 
apoptosis of cells, most likely through SHI triggering changes in the ERK1/2, 
JNK1/2 and p38α/β signalling pathways. In addition, the results show that SHI 
differentially regulates the expression of Bcl-2, Bax, Cytochrome c and caspase 3. 
This data also demonstrated that p-ERK is an up-stream regulator mediating the 
expression of Bcl-2 and caspase 3. It has been reported that reduced Bcl-2 and 
increased Bax expression leads to the release of Cytochrome c from the mitochondria 
to the cytoplasm (Dorjgochoo et al., 2013; Park et al., 2013). Cytochrome c 
combines with Apaf-1, which further activates caspase 3 to trigger cell apoptosis 
(Sun et al., 2012). These findings are summarised in Table 8. 
 
NF-κB has been widely demonstrated to regulate apoptosis and inflammation 
(Lappas, 2013; Yang et al., 2011). NF-κB is activated (phosphorylated) via the 
phosphorylation of IKK-α/β and degradation (phosphorylation) of I-κB (Gilmore, 
2006). Activated NF-κB translocates into the nucleus and then regulates the 
transcription of its target genes (Hoffmann et al., 2006). The data reported here 
demonstrates that SHI induces the degradation of I-κB and phosphorylation of NF-
κB in HSF, indicating the potential roles of NF-κB in SHI-induced apoptosis. 
Consistent with this finding, Kasibhatla et al. (1999) demonstrated that inhibition of 
NF-κB activity leads to reduced apoptosis in hybridoma cells (Kasibhatla et al., 
1999). However, conflicting findings can be found in the literatures. For example, 
Wang et al. (2014) reported that SHI induces apoptosis in cancer cell lines PANC-1, 
 Chapter 5: Effects of SHI on Transwell Co-cultured Kc and HSF 131 
BxPC-3 and AsPC-1 by suppressing the phosphorylation of NF-κB (Wang et al., 
2014). In addition, Li et al. (2013) demonstrated that SHI inhibits human T 
lymphocyte activation by suppressing the degradation of  I-κB (Li et al., 2013). 
Therefore, the roles of NF-κB in SHI-induced apoptosis in HSF need to be further 
investigated using a luciferase assay to identify NF-κB-regulated gene transcription. 
 
Kc also play important roles in wound healing and HS formation. Indeed it has 
been reported that if wound closure takes more than 21 days, then the probability of 
the wound developing into a HS is more than 78% (Deitch et al., 1983). Although 
my results show that SHI also inhibits Kc proliferation and induces Kc apoptosis 
through the same signalling pathways as in HSF, higher concentration of SHI (3 
µg/mL) are required to activate those signalling pathways in Kc compared to that 
observed in HSF. In other words, SHI can inhibit HSF proliferation and induce HSF 
apoptosis without affecting Kc function when applied at specific concentrations (1 
µg/mL). These results further support the potential use of SHI as a novel scar 
treatment since they suggest that SHI may be able to be applied to inhibit excessive 
fibroblast proliferation during HS formation while having little effect on the re-
epithelialization function of Kc.    
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Table 8. Summary of SHI-induced protein changes in Kc and HSF 
 
 Kc 
 24 h 48 h 
 SHI 
0.5 µg/mL 
SHI 
1 µg/mL 
SHI 
3 µg/mL 
SHI 
0.5 µg/mL 
SHI 
1 µg/mL 
SHI 
3 µg/mL 
p-ERK _ _ ↑ _ _ ↑ 
p-JNK _ _ _ _ _ ↑ 
p-p38 _ _ _ _ _ ↓ 
Caspase 3 _ _ _ _ _ ↓ 
Bcl-2 _ _ _ _ _ ↓ 
 HSF 
 24 h 48 h 
 SHI 
0.5 µg/mL 
SHI 
1 µg/mL 
SHI 
3 µg/mL 
SHI 
0.5 µg/mL 
SHI 
1 µg/mL 
SHI 
3 µg/mL 
p-ERK _ _ ↑ _ ↑ ↑ 
p-JNK _ _ ↑ _ ↑ ↑ 
p-p38 _ _ ↓ _ ↓ ↓ 
Caspase 3 _ _ ↓ _ ↓ ↓ 
Bcl-2 _ _ ↓ _ ↓ ↓ 
 
Table 7. SHI-induced protein changes in Kc and HSF.  “-” means unchanged; “↑” stands for up-
regulation; “↓” indicates down-regulation. 
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Another important factor underlying HS formation is the over-abundant 
amount of collagen produced by fibroblasts (Deng et al., 2013a). In normal wound 
healing the high level of collagen synthesis present in the early stages decreases and 
returns to normal tissue levels as the wound closes (Mutsaers et al., 1997). Deficient 
degradation or excessive production of collagen may therefore result in HS (Niessen 
et al., 1999). The data reported here indicates that SHI significantly down-regulates 
COL1A1 and COLA3A1 gene expression. In addition, ACTA2, a marker of 
myofibroblasts (a highly proliferative fibroblast type that produces more collagen 
than normal fibroblasts) (Hinz et al., 2001), was also attenuated after SHI treatment. 
Interestingly, 0.5 µg/mL of SHI decreases COL1A1 and ACTA2 gene expression in 
HSF, while no effect of SHI on HSF proliferation or apoptosis was observed at this 
concentration. These data suggest that it might be possible to deliver SHI at 
concentrations that inhibit collagen production by fibroblasts without affecting cell 
proliferation. 
 
Cytokines, such as TGF-β1 (Penn et al., 2012), PDGF (Salgado et al., 2012) 
and VEGF (Zhu et al., 2005), are also involved in wound healing and HS formation 
processes. TGF-β1, a cytokine secreted by both Kc and fibroblasts during wound 
healing, has been reported to be up-regulated in HS tissues (Colwell et al., 2005; 
Wang et al., 2000a). Furthermore, TGF-β1 from Kc stimulates fibroblasts to become 
myofibroblasts (Desmouliere et al., 1993). In contrast, TGF-β1 secreted by 
fibroblasts induces Kc to return to an inactive state at the end stage of wound healing 
(Freedberg et al., 2001). My results suggest that SHI attenuates the expression of 
TGF-β1 in Kc-HSF co-culture conditioned medium, further supporting the concept 
of SHI as a potential therapy for HS. While I also employed an ELISA assays to 
examine the expression of PDGF and VEGF, the concentration of PDGF and VEGF 
in the Transwell® “conditioned” medium was too low to be detected using an ELISA 
approach. The effect of SHI on those cytokines needs to be further evaluated using 
different approaches, such as in animal scar models. 
 
In conclusion, the excessive proliferation of fibroblasts, over-abundant 
production of collagen and delayed Kc function are three essential aspects linked to 
HS formation. In this chapter I have demonstrated for the first time that SHI inhibits 
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HSF proliferation and induces apoptosis without affecting Kc function at select 
concentrations. In addition, SHI has been demonstrated to reduce collagen 
production in HSF and to attenuate TGF-β1 expression in Kc-HSF co-culture 
“conditioned” medium. This data not only improves our understanding of the 
bioactivities of SHI in both Kc and HSF, but also suggests that SHI as a potential 
treatment for HS warrants further investigation. 
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Chapter 6: Effect of SHI on TGF-β1-
stimulated HSF 
6.1 INTRODUCTION 
Members of the TGF-β family of cytokines have been widely reported to play 
important roles in inflammation, ECM deposition and proliferation during tissue 
regeneration and wound healing processes. There are 3 known isoforms of TGF-β: 
TGF-β1, 2 and 3 (Schiller et al., 2004). TGF-β1 is activated via binding to its 
receptors (TβR I and II) (Cheifetz et al., 1988). Evidence indicates that TGF-β1 
regulates inflammation via mediating the proliferation of macrophages (Fan et al., 
1992). TGF-β1 also stimulates the differentiation of fibroblasts into myo-fibroblasts 
(Desmouliere et al., 1993) and inhibits matrix metalloproteinases activity (Mauviel, 
2005).  
 
TGF-β1 is considered to be significant in the formation of HS as elevated 
levels of TGF-β1 are often observed in HS tissue (Tredget et al., 2006). It has been 
demonstrated that abnormally elevated TGF-β1 during wound healing leads to the 
over-accumulation of ECM, causing the formation of HS (Wang et al., 2008). TGF-
β1 has also been found to stimulate fibroblast contraction during wound healing, 
which in turn contributes to the formation of HS (Zhang et al., 2009b). Smad 
proteins, downstream substrates in the TGF-β receptor-stimulated pathways, become 
phosphorylated by TβR I and translocates to the nucleus (Derynck et al., 1998). In 
the nucleus, phosphorylated Smad2/3 directly mediates the transcription of the 
COL1A1 gene (Upadhyay et al., 2013). In this chapter, investigations into the effect 
of SHI on TGF-β1-stimulated HSF are reported. These were undertaken to probe the 
mechanisms underlying SHI activity. The data reported in this chapter has been 
published by International Journal of Molecular Medicine (Fan et al., 2015). 
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6.2 METHODS 
HSF (6 × 104) were seeded into 12-well cell culture plates and treated with 
different concentrations of SHI (0, 0.5 and 1 µg/mL) accompanied with 5 ng/mL 
TGF-β1 for 72 h. The effect of SHI on TGF-β1-stimulated HSF viability was 
measured using the Alamar Blue assay as described in Section 3.4.2. The effect of 
SHI on TGF-β1-stimulated HSF collagen synthesis was evaluated with Sirius red 
histochemistry following the protocol described in Section 3.4.6. The effects of SHI 
on TGF-β1-stimulated HSF cell contraction were examined using the cell contraction 
assay as described in Section 3.4.7. The whole cell lysis was collected at 30 and 60 
min following SHI treatment. The total protein concentration was measured using 
BCA assay as per the manufacturer's instructions and then western blot was used to 
detect the expression of target proteins as described in Section 3.5.1. Total RNA was 
extracted at 24 and 48 h following SHI treatment. The first strand cDNA was 
synthesized using SuperscriptTM III Reverse Transcriptase. RT-PCR was performed 
on an ABI 7500 Thermal Cycler as described in Section 3.5.2. One-way ANOVA 
and Tukey’s post-hoc test were applied and p < 0.05 (ie. 95% confidence) was 
considered to be statistically significant. 
 
6.3 RESULTS 
6.3.1 SHI Attenuates TGF-β1 Stimulated HSF Viability 
The effects of TGF-β1 and SHI on HSF viability were evaluated using Alamar 
Blue assay. As shown in Figure 6.1, TGF-β1 (5 ng/mL) alone up-regulated HSF 
viability by 9.9% ± 1.3% compared to the control (no treatment) (p < 0.05). SHI at 
0.5 µg/mL had no effect on the viability of TGF-β1-stimulated HSF, while SHI at 1 
µg/mL reduced TGF-β1-stimulated HSF viability by 2.3% ± 0.6% compared to the 
control (p < 0.05). These data indicate that SHI reduces TGF-β1-induced HSF 
viability in a dose-dependent manner. 
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Figure 6.1. Effects of SHI on HSF viability.  All experiments were repeated 3 times using cells from 3 
different patients (biological replicates n = 3); for cells from each patient, the experiments were 
performed at least 3 times (technical replicates N = 3). The data was pooled as the percentage of the 
untreated control. Statistical analysis was performed using One-way ANOVA with Tukey’s post-test. 
#p < 0.05 versus the control. *p < 0.05 versus the TGF-β1 group. Error bar = SEM (n=3).  
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6.3.2 SHI Reduces TGF-β1 Induced Collagen Production in HSF 
As explained previously, over-abundant production of collagen is a key 
contributor to the development of HS (Varkey et al., 2011). Therefore, I evaluated 
the effect of TGF-β1 and SHI on collagen production in HSF using Sirius Red 
histochemistry. Sirius Red staining is a common method applied to measure the total 
amount of collagen present in tissues or cells (Rodriguez-Rodriguez et al., 2013). 
 
As shown in Figure 6.2 A, increased collagen (red staining) was observed in 
HSF treated with TGF-β1 compared to the untreated control. However, decreased 
amounts of collagen were detected in TGF-β1-stimulated HSF when also exposed to 
SHI at 0.5 and 1 µg/mL. Quantitative analysis of the HSF staining (Figure 6.2 B) 
indicates that TGF-β1 alone significantly increased the total amount of collagen by 
31.4% ± 1.5% compared to the untreated control (p < 0.05). However, the addition of 
SHI at 0.5 and 1 µg/mL attenuated TGF-β1-stimulated HSF collagen production by 
9.7% ± 0.7% and 27.4% ± 1.9%, respectively, compared to the TGF-β1 only group 
(p < 0.05). This data suggests that SHI is a potential inhibitor of the TGF-β1-
stimulated collagen production in HSF. 
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Figure 6.2. Effect of SHI on collagen production in TGF-β1-stimulated HSF. (A) Sirius red staining; 
(B) Quantitative analysis of collagen production. Images were captured using a Nikon SMZ800 
microscope. Representative images are shown. Quantitative data were expressed as the average 
percentage of the control. All experiments were repeated 3 times using cells from 3 different patients 
(biological replicates n = 3); for cells from each patient, the experiments were performed at least 3 
times (technical replicates N = 3). Statistical analysis was performed using One-way ANOVA with 
Tukey’s post-test.  #p < 0.05 versus the control (no TGF-β1 or SHI treatment). *p < 0.05 versus the 
TGF-β1 group. Error bar = SEM (n=3).  
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6.3.3 SHI Suppresses TGF-β1 Induced HSF Contraction  
Fibroblast-mediated wound contraction occupies an important role at the end of 
wound healing (Eldardiri et al., 2012). Excessive contraction in wound healing is 
known to contribute to the formation of HS (Desmouliere et al., 2003), therefore, the 
effect of SHI on TGF-β1-stimulated contraction in HSF was investigated. 
 
Treatment of HSF with TGF-β1 alone (Figure 6.3) stimulated significant gel 
contraction by HSF by 7.7% ± 2.2%, 28.4% ± 1.4% and 40.3% ± 5.0% at 12, 24 and 
48 h, respectively, compared to the untreated control group (p < 0.05). The 
contraction measured in HSF treated with both TGF-β1 and 0.5 µg/mL SHI was 
14.1% ± 1.3%, 31.3% ± 2.3% and 37.5% ± 2.4%, above the control group (p < 0.05) 
at 12, 24 and 48 h, respectively. However, HSF treated with TGF-β1 and 1 µg/mL 
SHI were not significantly different to the control group (p < 0.05). Taken together, 
these results suggest that SHI attenuates TGF-β1-induced gel contraction by HSF in 
a dose-dependent manner. 
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Figure 6.3. Effect of SHI on gel contraction by TGF-β1-stimulated HSF. (A) Images of cell 
contraction; (B) Quantitative analysis of cell contraction. Images were captured using a Nikon 
SMZ800 microscope. Representative images are shown. The major and minor axes of each gel were 
measured and the gel size was calculated. Quantitative data were expressed as the average percentage 
of the control. All experiments were repeated 3 times using cells from 3 different patients (biological 
replicates n = 3); for cells from each patient, the experiments were performed at least 3 times 
(technical replicates N = 3). Statistical analysis was performed using One-way ANOVA with Tukey’s 
post-test. #p < 0.05 versus the control. *p < 0.05 versus the TGF-β1 group. Error bar = SEM (n=3).  
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6.3.4 SHI-induced Gene Changes in HSF 
In order to identify the underlying mechanisms of SHI on the responses to 
TGF-β1-stimulated HSF, the expression of COL1A1, COL3A1, ACTA2 and SMAD2 
were assayed using RT-PCR. The COL1A1 and COL3A1 genes encode collagen type 
I and III, respectively. αSMA mediates the contraction of fibroblasts (Hinz et al., 
2001), while Smads are the downstream substrates of TGF-β receptors and are key 
mediators of collagen gene transcription (Upadhyay et al., 2013).  
 
HSF treated with TGF-β1 alone were found to significantly up-regulate 
COL1A1, ACTA2 and SMAD2 gene expression after 24 and 48 h compared to the 
control with no treatments (p < 0.05) (Figure 6.4). TGF-β1 had no effect on the 
expression of COL3A1 in HSF. However, when exposed to SHI at either 0.5 or 1 
µg/mL, the expression of COL1A1, COL3A1, ACTA2 and SMAD2 were significantly 
attenuated compared to HSF treated with TGF-β1. This is the first evidence that SHI 
suppresses TGF-β1-induced gene changes in HSF. 
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Figure 6.4. Effects of SHI on gene expression in TGF-β1-stimulated HSF.  (A) Expression of 
COL1A1; (B) Expression of COL3A1; (C) Expression of ACTA2; (D) Expression of SMAD2. The 
expression of the target genes were first normalized to GAPDH and then further converted to the 
percentage of the control (no TGF-β1 or SHI treatment). All experiments were repeated 3 times using 
cells from 3 different patients (biological replicates n = 3); for cells from each patient, the experiments 
were performed at least 3 times (technical replicates N = 3). Statistical analysis was performed using 
One-way ANOVA with Tukey’s post-test. #p < 0.05 versus the control. *p < 0.05 versus the TGF-β1 
group. Error bar = SEM (n=3). 
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6.3.5 SHI-induced Signalling Pathways 
The TGF-β1/Smad pathway is a comparatively simple signalling pathway, 
primarily involving the participation of TGF-β1, TGF-β1 receptor and Smad 2/3/4 
(Kamato et al., 2013). However, MAPKs are reported to regulate the TGF-β1/Smads 
signalling pathway. For example, ERK has been found to mediate phosphorylation of 
the linker region of Smads (Hough et al., 2012). Therefore, the expression of 
Smad2/3, p-Smad2/3 and p-ERK were characterised by Western blotting in HSF 
exposed to SHI and/or TGF-β1. 
 
Data reported in Figure 6.5 reveals that no effects of TGF-β1 and SHI were 
observed on the expression of ERK and Smad2/3 in HSF. However, the expression 
of p-ERK and p-Smad2/3 were significantly up-regulated in HSF after exposure to 
TGF-β1 alone for 30 min. In HSF treated with both TGF-β1 and SHI (either 0.5 or 1 
µg/mL) for 30 and 60 min the level of signalling proteins were decreased. 
Interestingly, the expression of αSMA was increased in HSF treated with TGF-β1 
alone after 30 and 60 min. In contrast the TGF-β1-induced up-regulation of αSMA 
was inhibited when HSF were also exposed to SHI (either 0.5 or 1 µg/mL) for 60 
min. 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 6: Effect of SHI on TGF-β1-stimulated HSF 146 
 
 
 Chapter 6: Effect of SHI on TGF-β1-stimulated HSF 147 
 
 
 Chapter 6: Effect of SHI on TGF-β1-stimulated HSF 148 
 
Figure 6.5. SHI-induced signalling pathways in TGF-β1-stimulated HSF.  (A) Expression of p-ERK; 
(B) Expression of p-Smad2/3; (C) Expression of αSMA. The expression of target signalling proteins 
was detected using the Odyssey Infrared Imaging system. GAPDH was included as a loading control. 
Most representative images were presented. At least 3 blots were performed. Bands from different 
treatment are derived from the same blot, while bands from different time points are derived from the 
different blots. For quantitative analysis, the intensities of the bands were measured with 
densitometry, normalized to GAPDH and then further converted to the percentage of the control (no 
TGF-β1 or SHI treatment). All experiments were repeated 3 times using cells from 3 different patients 
(biological replicates n = 3); for cells from each patient, the experiments were performed at least 3 
times (technical replicates N = 3). Statistical analysis was performed using One-way ANOVA with 
Tukey’s post-test. #p < 0.05 versus the control. *p < 0.05 versus the TGF-β1 group. Error bar = SEM 
(n=3).  
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6.4 DISCUSSION 
TGF-β1 is a multifunctional cytokine regulating cell proliferation, collagen 
production, cell differentiation and ECM degradation during wound healing 
processes (Liu et al., 2014a). Enhanced levels of TGF-β1 in cutaneous wound 
healing often leads to the formation of HS (Wang et al., 2000b). Based on our 
previous studies, I therefore investigated the effects of SHI on TGF-β1-stimulated 
HSF. 
 
In the early stage of wound healing fibroblasts migrate to the wound lesion and 
produce collagen, assisting replacement of the blood clot with new granulation 
tissues (Singer & Clark, 1999). The excessive collagen is degraded by proteases, 
such as collagenases, at the end of wound healing (Urioste et al., 1999). TGF-β1 has 
been demonstrated to play essential roles in the production of collagen by regulating 
the Smad2/3 signalling pathways (Wang et al., 2000b). Following binding of TGF-
β1 with its receptor (TβR-I), phosphorylation of Smad2/3 protein occurs 
intracellularly (Piek et al., 1999). Phosphorylated Smad2/3 will then 
heteromultimerize with Smad4 resulting in transfer into the nucleus and triggering 
expression of target genes, such as COL1A1 (Wrana & Attisano, 2000). Consistent 
with previous studies, my data suggest that TGF-β1 increases total collagen 
production, phosphorylates Smad2/3 and up-regulates COL1A1 gene expression in 
HSF. However, these changes induced by TGF-β1 in HSF are significantly 
attenuated when SHI treatment is concomitantly applied, indicating that SHI 
attenuates TGF-β1-induced collagen production in HSF. 
 
TGF-β1-induced Smad2/3 signalling has been reported to be associated with 
the activation of mitogen-activated protein kinases (MAPKs), including extracellular 
signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK) and mitogen-
activated protein kinase 14 (p38) (Massague, 2003). The linker region of Smads, in 
particular, plays essential roles in mediating Smad function (Inman, 2005). Studies 
indicate that ERK phosphorylates the linker region of Smad 2/3, thereby regulating 
the function of Smad2/3 in fibroblasts (Derynck & Zhang, 2003; Hough et al., 2012). 
Additionally, ERK inhibitors significantly block the phosphorylation of the Smad 
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linker region (Li et al., 2010). Furthermore, activation of ERK has been observed to 
enhance the duration of Smad2/3 transcriptional activity (Hough et al., 2012). To 
investigate the underlying mechanisms of SHI-induced collagen reduction in TGF-β1 
stimulated HSF, the expression of MAPKs after SHI treatment was investigated. The 
results indicated that no expression of phosphorylated JNK (p-JNK) and p38 (p-p38) 
was evident in HSF after treatment with TGF-β1 and SHI (data not shown); however, 
SHI significantly attenuated TGF-β1-induced phosphorylation of ERK (p-ERK) in 
HSF. These data suggest that SHI reduces TGF-β1-induced collagen production in 
HSF via the ERK/Smad signalling pathway. 
 
During the formation of granulation tissue some dermal fibroblasts change 
their phenotype to become myofibroblasts, which are responsible for wound 
contraction (Darby & Hewitson, 2007). Contraction is essential for the wound 
healing process as it reduces the wound size, thereby enabling wound closure; 
however, excessive wound contraction leads to the formation of HS (Zhang et al., 
2009a). Myofibroblasts, cells characterised by the presence of αSMA (Franz et al., 
2009), have been demonstrated to play key roles in HS formation (Ibrahim et al., 
2014). Indeed, increased expression of αSMA has been widely reported in HS tissues 
(Wang et al., 2008). TGF-β1 has been found to up-regulate over-expression αSMA 
as TGF-β1 stimulates normal fibroblasts to differentiate into myofibroblasts (Varga 
& Abraham, 2007). The experiments reported herein indicate that TGF-β1 improves 
the ability of HSF to contract gels, as well as enhances the expression of αSMA in 
HSF. Moreover, SHI attenuates TGF-β1-induced cell contraction and αSMA up-
regulation in HSF in a dose-dependent manner. 
 
Taken together, the data presented indicate that TGF-β1 plays key roles in 
cellular processes important to wound healing and HS formation. In particular, 
increased levels of TGF-β1 may lead to the formation of HS by stimulating collagen 
production and wound contraction. Further, this study indicates for the first time that 
SHI reduces TGF-β1-induced collagen production via the ERK/Smad signalling 
pathway and attenuates TGF-β1-induced gel contraction by HSF by down-regulating 
αSMA expression. This evidence supports the potential use of SHI as novel HS 
treatment. 
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Chapter 7: General Discussion 
HS remains a significant clinical problem, particularly in countries with open 
fires and poor infrastructure. In spite of many decades of research, the pathological 
mechanisms of HS are poorly understood (Simon et al., 2012). It has been 
demonstrated that HS formation results from dysregulation in the wound healing 
process (Sun et al., 2011). Prolonged inflammation (Liu et al., 2013b), over-
abundant production of collagen (Huang et al., 2013), excessive contraction at the 
wound site (Gauglitz et al., 2011), reduced apoptosis of fibroblasts (Liu et al., 2013a) 
or delayed wound closure (also called re-epithelialisation) (Simon et al., 2012) have 
all been reported to lead to the formation of HS. Current scar-remediation therapies 
are less than satisfactory for a number of reasons (Gabriel, 2011), hence attention has 
been given to the potential benefits of natural products as an alternative strategy to 
remediate scars (Wananukul et al., 2013).  
 
In the studies reported herein, SHI, an active component extracted from the 
traditional Chinese herbal medicine Radix Arnebiae, has been demonstrated to 
specifically induce apoptosis in HSF without concomitantly affecting Kc 
proliferation. The underlying mechanisms have also been revealed. Of particular 
novelty, these studies demonstrate that SHI reduces TGF-β1-stimulated HSF 
collagen production and cell contraction via the ERK/Smad signalling pathways. 
Collectively, these findings provide compelling evidence supporting the potential 
clinical use of SHI as a novel HS treatment. 
 
It is well described that fibroblasts (myofibroblasts) undergo apoptosis in the 
late phase of wound healing (Bainbridge, 2013). It has been shown that HS have a 
four-fold decrease in fibroblast apoptosis compared with that found in normal wound 
scars (Aarabi et al., 2007). In the absence of fibroblast apoptosis, however, the 
formation of HS ensues (van der Veer et al., 2009). In addition, Kc also play 
important roles in HS formation. For example, clinical evidence has demonstrated 
that if wound closure, or re-epithelialisation, takes more than 21 days, then the 
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probability of the wound developing into a HS is greater than 78% (Deitch et al., 
1983). For this reason I was concerned that any effect of SHI on wound closure may 
be counterproductive. The results indicated that SHI inhibits Kc and HSF 
proliferation in a dose-dependent manner. However, at low doses (< 3µg/mL), SHI 
selectively reduces HSF but not Kc proliferation. This dose-dependent proliferation-
inhibiting ability of SHI is of interest and greatly benefits its clinical potential. 
Indeed, it is not unreasonable to foresee an optimised formulation in which SHI only 
inhibits the over-proliferation of fibroblasts in HS without affecting the re-
epithelialisation process. Such optimisation studies are beyond the time frame of this 
PhD study, however, the data produced offers sufficient evidence to warrant further 
development of SHI as a HS therapy. 
 
MAPK proteins, including ERK1/2, JNK1/2 and p38α/β, have been widely 
demonstrated to play vital roles in the regulation of cell proliferation and apoptosis 
(Cagnol & Chambard, 2010a). The data reported herein suggest that the 
proliferation-inhibiting and apoptosis-inducing ability of SHI are most likely effected 
through the MAPK signalling pathways. ERK, the first indentified MAPK member 
(Boulton et al., 1990), plays key roles in cell proliferation and apoptosis (Bavaria et 
al., 2014; Lee et al., 2014b). My experiments revealed that SHI up-regulates the 
phosphorylation of ERK in Kc and HSF; however, reports by others provide contrary 
data. Consistent with my results, Shen et al. (2012) demonstrated that SHI increases 
the expression of p-ERK in human gastric cancer-7901 cells (Shen et al., 2012). 
However, Gwon et al. (2013) report that SHI inhibits the phosphorylation of ERK in 
3T3-L1 cells (Gwon et al., 2013). I also found that SHI increased the expression of 
p-JNK in Kc and HSF, a result consistent with that observed in other cells. For 
example, SHI up-regulates p-JNK expression in human gastric cancer-7901 cells 
(Shen et al., 2012), and also in myelogenous leukemia cells (Mao et al., 2008). My 
results also revealed that the level of phosphorylated p38, an essential mediator of 
the cell cycle (Thornton & Rincon, 2009), is down-regulated in Kc and HSF 
following SHI treatment. Consistent with this, Li et al. (2013) also reported that SHI 
reduces p-p38 expression in human T lymphocyte cells (Li et al., 2013). These data 
suggest that SHI-induced inhibition of cell proliferation and apoptosis is mediated 
via the ERK, JNK and p38 signalling pathways. 
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The effect of SHI on cell death was also examined. The results from TUNEL 
assays and flow cytometry demonstrate, for the first time, that SHI induces apoptosis 
in co-cultured Kc and HSF in a dose-dependent manner. As mentioned in Chapter 2, 
there are two classic apoptosis signalling pathways: the extrinsic (death receptor) and 
the intrinsic (mitochondrial) pathway. The extrinsic pathway is initiated by the 
ligation of death receptors, resulting in the activation of caspase 8 (Rubio-Moscardo 
et al., 2005). Caspase 8 further activates caspase 3, which finally executes apoptotic 
cell death (Fiandalo et al., 2013). I examined caspase 8 and found that no expression 
of caspase 8 could be detected in HSF (data not shown). However, Han et al. (2012) 
reported that SHI attenuates caspase 8 expression in leukemia cells (Han et al., 
2012a). From a survey of the literature, it is evident that SHI induces apoptosis in 
different cell types via different signalling pathways. Therefore, while I established 
that SHI induces apoptosis in Kc and HSF, it does not appear to be through the 
extrinsic apoptosis pathway. 
 
The intrinsic pathway is induced by death receptor-independent stimuli that 
directly target mitochondria (Huang et al., 2014a). The intrinsic pathway results in 
the down-regulation of Bcl-2 and up-regulation of Bax in the mitochondria, causing 
the release of cytochrome c (Saelens et al., 2004). Upon the release of Cytochrome c 
into the cytoplasm, Cytochrome c binds with Apaf-1 and procaspase-9 to form the 
“apoptosome”. The apoptosome induces apoptosis by further activating caspase 3 
(Hill et al., 2004). The results reported in chapter 5 indicate that SHI reduces Bcl-2 
expression and induces cleavage of caspase 3 in Kc and HSF at both the mRNA and 
protein level. In addition, the data also demonstrated that SHI-induced reduction of 
Bcl-2 and cleavage of caspase 3 is mediated by the phosphorylation of ERK. This is 
consistent with results reported by others. For example, SHI is reported to reduce 
Bcl-2 expression in human breast carcinoma MCF-7 cells (Xiong et al., 2013). 
Furthermore, Bax and cytochrome c have been found to be up-regulated in human 
breast carcinoma MCF-7 cells (Xiong et al., 2013), human colorectal cancer cells 
(Fan et al., 2012b) and human lens epithelial cells (Huang et al., 2014b). I did not, 
however, observe a similar up-regulation of protein expression of Bax and 
cytochrome c in Kc and HSF in my study. Up-regulation of Bax and cytochrome c at 
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the mRNA level (BAX and CYCS) in Kc and HSF following SHI treatment was 
nevertheless observed.  
 
NF-κB is another essential signalling pathway regulating cell apoptosis and 
inflammation (Lappas, 2013; Yang et al., 2011). NF-κB is activated 
(phosphorylated) via the phosphorylation of IKK-α/β and degradation 
(phosphorylation) of  I-κB (Gilmore, 2006). It has been reported that SHI induces 
apoptosis in cancer cell lines PANC-1, BxPC-3 and AsPC-1 by suppressing the 
phosphorylation of NF-κB (Wang et al., 2014). However, Kasibhatla et al. (1999) 
demonstrated that inhibition of NF-κB activity leads to reduced apoptosis in 
hybridoma cells (Kasibhatla et al., 1999). Moreover, evidence indicates that 
activation of NF-κB leads to increased transcription of anti-apoptotic genes, such as 
Bcl-2, thus preventing cells from apoptosis (Posadas et al., 2012). Conversely, other 
studies suggest that activation of NF-κB is accompanied with decreased Bcl-2 
expression (Miniati et al., 2001). My studies, however, indicate degradation of I-κB 
and phosphorylation of NF-κB in HSF when treated with SHI, suggesting the 
potential roles of NF-κB in SHI-induced apoptosis. Clearly, additional studies are 
required to determine the exact roles of NF-κB in SHI-induced apoptosis in HSF; this 
could for example be provided through the use of luciferase assay to determine NF-
κB-regulated gene transcription in HSF when treated with SHI. 
 
The over-abundant production of collagen by fibroblasts is the most obvious 
physical manifestation of HS formation (Deng et al., 2013a). Therefore reducing 
collagen is critical for the design of any novel HS treatment. I report here, for the 
first time, that SHI reduces the total amount of collagen in HSF. SHI was found to 
down-regulate the expression of the COL1A1 and COL3A1 genes in HSF. These 
genes encode collagen type I and III, respectively. However, it needs to be borne in 
mind that SHI-induced apoptosis may also contribute to the reduction in collagen as 
fewer cells will produce less collagen. The expression of the ACTA2 gene was also 
attenuated in HSF following SHI treatment. αSMA is characteristic of 
myofibroblasts, which are more proliferative and produce more collagen than 
“normal” fibroblasts (Hinz et al., 2001). An intriguing finding in my study is that 
SHI at 0.5 µg/mL decreases COL1A1 and ACTA2 gene expression in HSF, while no 
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effect of SHI on HSF proliferation or apoptosis was observed at this concentration. 
This suggests that SHI might be formulated as a novel HS treatment that specially 
targets collagen production by fibroblasts without necessarily affecting cell 
proliferation.  
 
Taken together, my data demonstrate that SHI inhibits Kc and HSF 
proliferation and induces apoptosis in Kc and HSF in a dose-dependent manner. In 
particular, I found that SHI selectively induces apoptosis in HSF but not in Kc when 
applied at certain concentrations (1 µg/mL). I investigated the molecular mechanism 
of SHI activity and found that SHI inhibits the cell proliferation via the MAPK 
signalling pathways, and induces apoptosis via the mitochondria apoptosis signalling 
pathway. The putative signalling pathways triggered by SHI are summarised in 
Figure 7.1. 
 
 
 
Figure 7.1. Intracellular signalling pathways effected by SHI treatment. “↑” = activation, or up-
regulation; “↓” = inhibition, or down-regulation. 
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The wound healing cascade is exquisitely regulated by a large variety of 
growth factors and cytokines. Cytokines, such as TGF-β1, PDGF and VEGF, 
contribute to both wound healing and HS formation (Penn et al., 2012; Salgado et 
al., 2012). However, little is known about the effect of SHI on the expression and 
activity of those cytokines. A single study reports that SHI increases the expression 
of TGF-β1 in IEC-18 small intestinal cells (Andujar et al., 2013). My results 
indicated that SHI attenuates the expression of TGF-β1 in Transwell co-cultured Kc 
and HSF. These findings not only contribute to the understanding of the effects of 
SHI on cytokines, but also offers evidence supporting the potential use of SHI as a 
novel HS treatment, since expression of TGF-β1 has been widely demonstrated to 
induce HS formation (Colwell et al., 2005; Wang et al., 2000a). While there are no 
reports on the effects of SHI on PDGF in the literature, Lee et al. (2008) reported 
that SHI inhibits VEGF-induced angiogenesis in Lewis lung carcinoma-bearing mice 
(Lee et al., 2008). SHI has also been reported to attenuate VEGF expression in 
human prostate cancer cell lines (Gaddipati et al., 2000). While we did not examine 
angiogenesis, SHI may well have effects on endothelial cells. Future studies 
focussing on VEGF are warranted given the key role of neovascularization in tissue 
repair and wound healing.  
 
My experimental evidence revealed that TGF-β1 is down-regulated in Kc-HSF 
co-culture “conditioned” medium following SHI treatment. In order to further 
investigate how the action of SHI on TGF-β1 might benefit its potential therapeutic 
use, I examined the effects of SHI on TGF-β1-stimulated HSF. TGF-β1 regulates 
fibroblast collagen production via the Smad2/3 signalling pathways (Wang et al., 
2000b). Binding of TGF-β1 with its receptor (TβR-I) leads to the phosphorylation of 
Smad2/3 (Piek et al., 1999), and phosphorylated Smad2/3 then transfers into the 
nucleus and regulates the expression of target genes, such as COL1A1 (Wrana & 
Attisano, 2000). My results confirmed that TGF-β1 stimulates the expression of p-
Smad2/3 and COL1A1, total amount of collagen produced by HSF and enhanced cell 
contraction. These studies also indicated that SHI is a potent inhibitor of TGF-β1-
induced collagen production in HSF.  
 
 Chapter 7: General Discussion 157 
While this is the first report of SHI activity on collagen production, other 
reagents have been reported to possess similar properties. For example, Sp1 decoy 
oligodeoxynucleotide has been shown to attenuate the collagen production by HSF 
(Deng et al., 2013b), while Wu et al. (2014) reported that Astragalus and Salvia 
miltiorrhiza extract reduces HSF collagen production via the TGF-β/Smad signalling 
pathway (Wu et al., 2014a). In addition, liposome-enveloped Ligusticum chuanxiong 
essential oil was shown to down-regulate collagen production by HSF in a rabbit scar 
model (Zhang et al., 2012).  
 
Numerous studies have demonstrated that TGF-β1 induces collagen production 
in fibroblasts via the Smad signalling pathway (Kamato et al., 2013). My data 
confirm the reduction of collagen synthesis by TGF-β1-stimulated HSF is 
accompanied by decreased of p-Smad2/3. While TGF-β/Smad is an uncomplicated 
signalling pathway, increasing evidence suggests that the TGF-β/Smad signalling 
pathway is mediated by the MAPK family of proteins (Massague, 2003). Evidence 
indicates that ERK regulates Smad2/3 function via phosphorylating the linker region 
of Smad 2/3 (Derynck & Zhang, 2003; Hough et al., 2012). Inhibitors of ERK also 
inhibit the phosphorylation of the Smad linker region (Li et al., 2010). In addition, 
activation of ERK has been observed to increase the duration of Smad2/3 
transcriptional activity (Hough et al., 2012). My results further support the link 
between ERK activity and Smad2/3 phosphorylation, since SHI-induced down-
regulation of p-Smad2/3 in TGF-β1-stimulated HSF is accompanied by a reduction 
of p-ERK expression. 
 
During the wound healing cascade of events, a subset of fibroblasts modifies 
their phenotype to become myofibroblasts. Myofibroblasts have been demonstrated 
to regulate wound contraction (Darby & Hewitson, 2007); this contraction is 
essential for the wound healing process as it reduces the wound size, thereby 
enabling wound closure. However, excessive wound contraction leads to the 
formation of HS (Zhang et al., 2009a). Enhanced expression of αSMA is often 
observed in HS tissues (Wang et al., 2008). In fact, αSMA is considered as an unique 
marker of myofibroblasts (Franz et al., 2009). Of note, TGF-β1 is reported to 
contribute to the over-expression of αSMA (Varga & Abraham, 2007). In my study, I 
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observed that TGF-β1 enhances cell contraction by HSF and increases αSMA 
expression in HSF, at both the transcriptional and translational levels. This is 
consistent with previous findings. In addition, SHI has been demonstrated to 
attenuate TGF-β1-induced contraction and αSMA expression in HSF. These data 
further substantiate the clinical potential use of SHI on HS treatment. 
 
Taken together, my studies confirmed that TGF-β1 increases collagen 
production and cell contraction in HSF. In addition, I demonstrated that SHI, for the 
first time, inhibits TGF-β1-induced collagen production and cell contraction in HSF. 
Putative signalling pathways for these actions are summarised in Figure 7.2. 
 
 
 
Figure 7.2. Putative signalling pathways triggered following SHI treatment in TGF-β1-stimulated 
HSF.  “P” indicates phosphorylation; Red line indicates “Inhibition”. 
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In addition to the studies reported in this thesis, I collaborated with others to 
investigate the effect of SHI as an anti-inflammatory agent. Studies on 
lipopolysaccharide (LPS)-stimulated human periodontal ligament cells (hPDLCs) 
demonstrated that SHI attenuates the expression of inflammatory cytokines, 
including IL-1, IL-6, TNF-α, matrix metalloproteinase-2 (MMP-2), MMP-9 and 
cyclooxygenase-2 (COX-2), in hPDLCs via activation of the NF-κB signalling 
pathway. This data suggests that SHI possesses anti-inflammatory activities and 
therefore can be potentially used in the treatment of periodontitis. A manuscript 
generated from this project has been accepted for publication by the Journal of 
Traditional Chinese Medicine (09/11/2014; ID: 14350). Given that excessive 
inflammation is a hallmark characteristic of delayed wound healing, these results 
suggest that the effect of SHI on inflammatory processes in skin cells should be 
examined. 
 
While the studies reported in this thesis have shed new light on the actions of 
SHI and its potential as a scar-remediation therapy, additional work is still required, 
and is beyond the time and resource constraints of this current project. For example, 
we initially aimed to investigate the effects of SHI on HS-related cells. For my 
Transwell study, I used Kc isolated from normal skin, while the fibroblasts were 
derived from HS tissue. Although my optimization studies (Chapter 4) demonstrated 
that normal Kc can interact with HSF, co-culture of hypertrophic scar-derived Kc 
and HSF would be more appropriate for this study. To pursue this, hypertrophic scar-
derived Kc were purchased from Cell Research Corporation; however, I was unable 
to propagate these cells in our laboratory, despite several attempts and much 
discussion with the supplier. Another limitation of the current research relates to the 
detection of cytokines in the Transwell co-culture medium. As shown in Chapter 5, I 
only observed the expression of TGF-β1 and PDGF in the Transwell co-culture 
medium. The threshold of detection of VEGF was greater than what would seem to 
be present in our samples. Thus, I was not able to assay for VEGF using ELISA 
assays. Other cytokines, such as IL-6 (Ray et al., 2013), IL-10 (Shi et al., 2014) and 
FGF (Spyrou & Naylor, 2002), are reported in the literature to also play important 
roles in HS formation, therefore it is recommended that the effects of SHI on other 
cytokines would further benefit the understanding of the therapeutic value of SHI. 
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Additionally, in Chapter 5, I demonstrated that SHI activates NF-κB signalling 
pathway in HSF, however, the exact roles of NF-κB in SHI-induced apoptosis in 
HSF is not clear. Therefore, investigating the roles of NF-κB in SHI-induced 
apoptosis using a luciferase assay to determine NF-κB-regulated gene transcription is 
another aspect worthy of pursuit.  
 
  Future studies that would improve our understanding of the therapeutic value 
of SHI include examining the effects of SHI using a 3-D model. As discussed in 
Chapter 4, the addition of extra growth factors might assist in the development of a 
relevant 3D scar tissue model. Alternatively, the effects of SHI on Kc and HSF could 
be investigated using the 3-D collagen gel model. This model has been widely used 
for similar studies, such as examination of the formation of vascular networks 
(Stamati et al., 2014) and fibroblast contraction (Liu et al., 2014b). Nevertheless, 
examining the effects of SHI using an animal HS model is key to truly evaluating the 
therapeutic potential of SHI.  
 
To date, the exact pathological mechanisms underpinning HS formation are 
still elusive. The lack of suitable animal models, in particular, is a major barrier 
towards gaining a better understanding the mechanisms of HS formation (Momtazi et 
al., 2013). The use of mouse and rabbit HS models has been previously reported 
(Momtazi et al., 2013; ZhiYong et al., 2012); however, rodent skin is anatomically 
and physiologically unlike human skin. Pig skin is recognised to be the closest 
animal model for human skin anatomically and physiologically (Sullivan et al., 
2001). In view of this, members at our group have developed a HS model in Large 
White pigs via deep dermal partial thickness burn injury (Cuttle et al., 2006). This 
model has been successfully used to test novel therapies for wound healing and 
scarring (Cuttle et al., 2008; Upton et al., 2008). The Large White pig model is also 
ideal for studies determining optimal dermal drug delivery (Eskandani & Nazemiyeh, 
2014). The assessment of SHI and various carriers and formulations in such animals 
is the key next step in progressing this research. 
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In conclusion, excessive proliferation of fibroblasts, over-abundant production 
of collagen, enhanced level of TGF-β1 and delayed Kc function lead to the formation 
of HS. In this PhD project, I have identified that SHI, an active component extracted 
from Radix arnebiae and used for traditional Chinese herbal medicine, inhibits HSF 
proliferation and induces HSF apoptosis without affecting Kc proliferation. The 
underlying mechanisms of SHI-induced apoptosis have also been revealed. In 
addition, SHI was found to attenuate expression TGF-β1 in Kc-HSF co-culture. SHI 
reduced TGF-β1-induced collagen production via the ERK/Smad signalling pathway 
and attenuated TGF-β1-induced gel contraction by HSF. SHI also down-regulated 
αSMA expression. These novel data suggest that SHI holds great potential to be 
developed into an anti-HS agent that could be used by clinicians to deliver 
therapeutic benefits to patients who suffer the unpleasant life-long burden of HS. 
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